{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 84,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import pandas as pd\n",
    "import csv\n",
    "import re\n",
    "import sys\n",
    "import math\n",
    "import nltk\n",
    "import string\n",
    "from sklearn.feature_extraction.text import TfidfVectorizer\n",
    "from nltk import word_tokenize\n",
    "from nltk.stem.porter import PorterStemmer\n",
    "from nltk.corpus import stopwords"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "## Retrieve current working directory (`cwd`)\n",
    "cwd = os.getcwd()\n",
    "cwd\n",
    "## Change directory \n",
    "current_file=os.chdir(\"C:\\\\treckchallenge\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Reading the Data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(22642, 4)"
      ]
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Load the data from excel in csv format\n",
    "data_with_features= pd.read_csv(\"C:\\\\treckchallenge\\\\20180622processedGoldStandardXMLTXT.tsv\", sep=\"\\t\", encoding=\"utf-8\", usecols=[\"pm_rel_desc\", \"title\", \"abstract\", \"trec_topic_disease\"])\n",
    "data_with_features.shape"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Getting Stop Words"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[nltk_data] Downloading package stopwords to\n",
      "[nltk_data]     C:\\Users\\Arpita.Kappattanavar\\AppData\\Roaming\\nltk_dat\n",
      "[nltk_data]     a...\n",
      "[nltk_data]   Package stopwords is already up-to-date!\n"
     ]
    }
   ],
   "source": [
    "#download stopwords\n",
    "nltk.download('stopwords')\n",
    "stop = stopwords.words('english')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Creating PM dataset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(9274, 4)"
      ]
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pmSet = data_with_features[data_with_features['pm_rel_desc'].str.contains('Human PM|Animal PM', regex=True)]\n",
    "pmSet.shape"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Something"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 93,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[nltk_data] Downloading package punkt to\n",
      "[nltk_data]     C:\\Users\\Arpita.Kappattanavar\\AppData\\Roaming\\nltk_dat\n",
      "[nltk_data]     a...\n",
      "[nltk_data]   Package punkt is already up-to-date!\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "['case',\n",
       " 'metastatic',\n",
       " 'liposarcoma',\n",
       " 'originating',\n",
       " 'retroperitoneum',\n",
       " 'successfully',\n",
       " 'treated',\n",
       " 'combination',\n",
       " 'chemotherapy',\n",
       " 'reported',\n",
       " '36-year-old',\n",
       " 'woman',\n",
       " 'metastatic',\n",
       " 'liposarcoma',\n",
       " 'originating',\n",
       " 'retroperitoneum',\n",
       " 'responded',\n",
       " 'well',\n",
       " 'adjuvant',\n",
       " 'chemotherapy',\n",
       " 'primary',\n",
       " 'tumor',\n",
       " 'removed',\n",
       " 'surgery',\n",
       " 'two',\n",
       " 'months',\n",
       " 'later',\n",
       " 'patient',\n",
       " 'developed',\n",
       " 'metastasis',\n",
       " 'brain',\n",
       " 'lung',\n",
       " 'four',\n",
       " 'months',\n",
       " 'later',\n",
       " 'metastatic',\n",
       " 'liposarcomas',\n",
       " 'brain',\n",
       " 'generally',\n",
       " 'extremely',\n",
       " 'rare',\n",
       " 'patient',\n",
       " 'treated',\n",
       " 'combination',\n",
       " 'chemotherapy',\n",
       " 'using',\n",
       " 'cyclophosphamide',\n",
       " 'vincristine',\n",
       " 'adriamycin',\n",
       " 'dacarbazine',\n",
       " 'cyvadic',\n",
       " 'examined',\n",
       " 'former',\n",
       " 'two',\n",
       " 'drugs',\n",
       " 'alternated',\n",
       " 'vindesine',\n",
       " 'ifosfamide',\n",
       " 'another',\n",
       " 'regimen',\n",
       " 'cisplatin',\n",
       " 'etoposide',\n",
       " 'given',\n",
       " 'three-week',\n",
       " 'interval',\n",
       " 'result',\n",
       " 'metastases',\n",
       " 'totally',\n",
       " 'disappeared',\n",
       " 'recurrent',\n",
       " 'lesion',\n",
       " 'noted',\n",
       " 'two',\n",
       " 'years',\n",
       " 'although',\n",
       " 'role',\n",
       " 'chemotherapy',\n",
       " 'liposarcoma',\n",
       " 'well',\n",
       " 'defined',\n",
       " 'little',\n",
       " 'data',\n",
       " 'support',\n",
       " 'use',\n",
       " 'adjuvant',\n",
       " 'setting',\n",
       " 'combination',\n",
       " 'chemotherapy',\n",
       " 'seemed',\n",
       " 'effective',\n",
       " 'advanced',\n",
       " 'liposarcoma',\n",
       " 'analysis',\n",
       " 'sas',\n",
       " 'gene',\n",
       " 'cdk4',\n",
       " 'mdm2',\n",
       " 'proteins',\n",
       " 'low-grade',\n",
       " 'osteosarcoma',\n",
       " 'region',\n",
       " 'q13-15',\n",
       " 'chromosome',\n",
       " '12',\n",
       " 'contains',\n",
       " 'sas',\n",
       " 'cdk4',\n",
       " 'mdm2',\n",
       " 'genes',\n",
       " 'rearranged',\n",
       " 'amplified',\n",
       " 'variety',\n",
       " 'human',\n",
       " 'sarcomas',\n",
       " 'study',\n",
       " 'evaluated',\n",
       " 'sas',\n",
       " 'gene',\n",
       " 'amplification',\n",
       " 'mdm2',\n",
       " 'cdk4',\n",
       " 'protein',\n",
       " 'expression',\n",
       " '20',\n",
       " 'tumor',\n",
       " 'samples',\n",
       " 'central',\n",
       " 'low-grade',\n",
       " 'osteosarcoma',\n",
       " '16',\n",
       " 'primary',\n",
       " '3',\n",
       " 'recurrences',\n",
       " '1',\n",
       " 'lung',\n",
       " 'metastasis',\n",
       " 'sas',\n",
       " 'amplification',\n",
       " 'analyzed',\n",
       " 'quantitative',\n",
       " 'polymerase',\n",
       " 'chain',\n",
       " 'reaction',\n",
       " 'pcr',\n",
       " 'paraffin-embedded',\n",
       " 'samples',\n",
       " 'mdm2',\n",
       " 'cdk4',\n",
       " 'protein',\n",
       " 'expression',\n",
       " 'evaluated',\n",
       " 'immunohistochemistry',\n",
       " 'mdm2',\n",
       " 'cdk4',\n",
       " 'proteins',\n",
       " 'found',\n",
       " 'strongly',\n",
       " 'expressed',\n",
       " '35',\n",
       " '65',\n",
       " 'respectively',\n",
       " 'samples',\n",
       " 'sas',\n",
       " 'found',\n",
       " 'amplified',\n",
       " '15',\n",
       " 'samples',\n",
       " 'findings',\n",
       " 'indicate',\n",
       " 'genes',\n",
       " 'may',\n",
       " 'involved',\n",
       " 'tumorigenesis',\n",
       " 'progression',\n",
       " 'low-grade',\n",
       " 'osteosarcoma',\n",
       " 'induction',\n",
       " 'secreted',\n",
       " 'protein',\n",
       " 'myxoid',\n",
       " 'liposarcoma',\n",
       " 'oncogene',\n",
       " 'tls-chop',\n",
       " 'oncoprotein',\n",
       " 'found',\n",
       " 'majority',\n",
       " 'human',\n",
       " 'myxoid',\n",
       " 'liposarcomas',\n",
       " 'consists',\n",
       " 'fusion',\n",
       " 'transcription',\n",
       " 'factor',\n",
       " 'chop/gadd153',\n",
       " 'n',\n",
       " 'terminus',\n",
       " 'rna-binding',\n",
       " 'protein',\n",
       " 'tls/fus',\n",
       " 'clinical',\n",
       " 'correlation',\n",
       " 'vitro',\n",
       " 'transformation',\n",
       " 'assays',\n",
       " 'indicate',\n",
       " 'n',\n",
       " 'terminus',\n",
       " 'tls',\n",
       " 'plays',\n",
       " 'important',\n",
       " 'role',\n",
       " 'oncogenesis',\n",
       " 'tls-chop',\n",
       " 'however',\n",
       " 'activity',\n",
       " 'attributed',\n",
       " 'oncoprotein',\n",
       " 'inhibiting',\n",
       " 'binding',\n",
       " 'transcription',\n",
       " 'factors',\n",
       " 'c/ebp',\n",
       " 'class',\n",
       " 'certain',\n",
       " 'adipogenic',\n",
       " 'target',\n",
       " 'genes',\n",
       " 'function',\n",
       " 'tls-chop',\n",
       " 'shares',\n",
       " 'nononcogenic',\n",
       " 'chop',\n",
       " 'protein',\n",
       " 'report',\n",
       " 'isolation',\n",
       " 'gene',\n",
       " 'dol54',\n",
       " 'activated',\n",
       " 'primary',\n",
       " 'fibroblasts',\n",
       " 'expression',\n",
       " 'tls-chop',\n",
       " 'dol54',\n",
       " 'expressed',\n",
       " 'neoplastic',\n",
       " 'component',\n",
       " 'human',\n",
       " 'myxoid',\n",
       " 'liposarcomas',\n",
       " 'increases',\n",
       " 'tumorigenicity',\n",
       " 'cells',\n",
       " 'injected',\n",
       " 'nude',\n",
       " 'mice',\n",
       " 'activation',\n",
       " 'dol54',\n",
       " 'requires',\n",
       " 'intact',\n",
       " 'dna-binding',\n",
       " 'dimerization',\n",
       " 'domain',\n",
       " 'tls-chop',\n",
       " 'suitable',\n",
       " 'cellular',\n",
       " 'dimerization',\n",
       " 'partner',\n",
       " 'depends',\n",
       " 'tls',\n",
       " 'n',\n",
       " 'terminus',\n",
       " 'normal',\n",
       " 'adipocytic',\n",
       " 'differentiation',\n",
       " 'associated',\n",
       " 'early',\n",
       " 'transient',\n",
       " 'expression',\n",
       " 'dol54',\n",
       " 'gene',\n",
       " 'encodes',\n",
       " 'secreted',\n",
       " 'protein',\n",
       " 'tightly',\n",
       " 'associated',\n",
       " 'cell',\n",
       " 'surface',\n",
       " 'extracellular',\n",
       " 'matrix',\n",
       " 'tls-chop',\n",
       " 'thus',\n",
       " 'leads',\n",
       " 'unscheduled',\n",
       " 'expression',\n",
       " 'gene',\n",
       " 'normally',\n",
       " 'associated',\n",
       " 'adipocytic',\n",
       " 'differentiation',\n",
       " 'mutations',\n",
       " 'tp53',\n",
       " 'amplification',\n",
       " 'egfr',\n",
       " 'mdm2',\n",
       " 'cdk4',\n",
       " 'deletions',\n",
       " 'cdkn2a',\n",
       " 'malignant',\n",
       " 'astrocytomas',\n",
       " 'investigated',\n",
       " 'frequency',\n",
       " 'mutual',\n",
       " 'relationship',\n",
       " 'molecular',\n",
       " 'alterations',\n",
       " '33',\n",
       " 'malignant',\n",
       " 'astrocytomas',\n",
       " '28',\n",
       " 'glioblastomas',\n",
       " '5',\n",
       " 'anaplastic',\n",
       " 'astrocytomas',\n",
       " 'genetic',\n",
       " 'alterations',\n",
       " 'analyzed',\n",
       " 'deletion',\n",
       " 'cdkn2a/p16',\n",
       " 'gene',\n",
       " 'tp53',\n",
       " 'mutations',\n",
       " 'amplification',\n",
       " 'egfr',\n",
       " 'mdm2',\n",
       " 'cdk4',\n",
       " 'common',\n",
       " 'genetic',\n",
       " 'alteration',\n",
       " 'egfr',\n",
       " 'amplification',\n",
       " 'revealed',\n",
       " '15',\n",
       " 'cases',\n",
       " '45',\n",
       " 'tp53',\n",
       " 'mutation',\n",
       " 'identified',\n",
       " '9',\n",
       " 'cases',\n",
       " '27',\n",
       " 'cdkn2/p16',\n",
       " 'deletion',\n",
       " 'detected',\n",
       " '13',\n",
       " 'cases',\n",
       " '41',\n",
       " 'either',\n",
       " 'mdm2',\n",
       " 'cdk4',\n",
       " 'amplifications',\n",
       " 'less',\n",
       " 'frequent',\n",
       " 'identified',\n",
       " '4',\n",
       " '12',\n",
       " '1',\n",
       " '3',\n",
       " 'case',\n",
       " 'respectively',\n",
       " '15',\n",
       " 'cases',\n",
       " 'showing',\n",
       " 'amplification',\n",
       " 'egfr',\n",
       " '9',\n",
       " 'cdkn2/p16',\n",
       " 'deletion',\n",
       " '60',\n",
       " 'p',\n",
       " '0.04',\n",
       " 'hand',\n",
       " 'cdkn2/p16',\n",
       " 'deletion',\n",
       " 'egfr',\n",
       " 'amplification',\n",
       " 'rarely',\n",
       " 'occurred',\n",
       " 'tp53',\n",
       " 'mutations',\n",
       " '2',\n",
       " '14',\n",
       " 'cases',\n",
       " 'cdkn2/p16',\n",
       " 'deletion',\n",
       " '14',\n",
       " 'results',\n",
       " 'confirm',\n",
       " 'existence',\n",
       " 'least',\n",
       " 'two',\n",
       " 'different',\n",
       " 'pathways',\n",
       " 'leading',\n",
       " 'formation',\n",
       " 'glioblastoma',\n",
       " 'case',\n",
       " 'advanced',\n",
       " 'retroperitoneal',\n",
       " 'dedifferentiated',\n",
       " 'liposarcoma',\n",
       " 'treated',\n",
       " 'effectively',\n",
       " 'high-dose',\n",
       " 'ifosfamide',\n",
       " 'report',\n",
       " 'case',\n",
       " 'retroperitoneal',\n",
       " 'dedifferentiated',\n",
       " 'liposarcoma',\n",
       " 'treated',\n",
       " 'effectively',\n",
       " 'high-dose',\n",
       " 'ifosfamide',\n",
       " '59-year-old',\n",
       " 'man',\n",
       " 'received',\n",
       " 'tumorectomy',\n",
       " 'right',\n",
       " 'nephrectomy',\n",
       " 'retroperitoneal',\n",
       " 'liposarcoma',\n",
       " 'twenty-two',\n",
       " 'months',\n",
       " 'operation',\n",
       " 'liver',\n",
       " 'metastasis',\n",
       " 'resected',\n",
       " 'incompletely',\n",
       " 'three',\n",
       " 'months',\n",
       " 'later',\n",
       " 'right',\n",
       " 'pleural',\n",
       " 'retroperitoneal',\n",
       " 'peritoneal',\n",
       " 'metastases',\n",
       " 'appeared',\n",
       " '6',\n",
       " 'cycles',\n",
       " 'high-dose',\n",
       " 'ifosfamide',\n",
       " 'therapy',\n",
       " 'tumors',\n",
       " 'reduced',\n",
       " 'partially',\n",
       " 'ten',\n",
       " 'cycles',\n",
       " 'chemotherapy',\n",
       " 'administered',\n",
       " 'tumors',\n",
       " 'showed',\n",
       " 'regrowth',\n",
       " '14',\n",
       " 'months',\n",
       " 'administration',\n",
       " 'high',\n",
       " 'dose',\n",
       " 'ifosfamide',\n",
       " 'combination',\n",
       " 'chemotherapy',\n",
       " 'ifosfamide',\n",
       " 'doxorubicine',\n",
       " 'etoposide',\n",
       " 'effective',\n",
       " 'regrowth',\n",
       " 'tumors',\n",
       " 'detection',\n",
       " 'p16',\n",
       " 'rb',\n",
       " 'cdk4',\n",
       " 'p53',\n",
       " 'gene',\n",
       " 'deletion',\n",
       " 'amplification',\n",
       " 'fluorescence',\n",
       " 'situ',\n",
       " 'hybridization',\n",
       " '96',\n",
       " 'gliomas',\n",
       " 'inactivation',\n",
       " 'p53',\n",
       " 'gene',\n",
       " 'common',\n",
       " 'early',\n",
       " 'event',\n",
       " 'astrocytoma',\n",
       " 'tumorigenesis',\n",
       " 'alternatively',\n",
       " 'since',\n",
       " 'p16',\n",
       " 'retinoblastoma',\n",
       " 'rb',\n",
       " 'cdk4',\n",
       " 'genes',\n",
       " 'implicated',\n",
       " 'malignant',\n",
       " 'progression',\n",
       " 'detection',\n",
       " 'losses',\n",
       " 'amplifications',\n",
       " 'genes',\n",
       " 'gliomas',\n",
       " 'could',\n",
       " 'diagnostically',\n",
       " 'prognostically',\n",
       " 'therapeutically',\n",
       " 'important',\n",
       " 'obtained',\n",
       " 'smear',\n",
       " 'preparations',\n",
       " '96',\n",
       " 'diffuse',\n",
       " 'gliomas',\n",
       " '10',\n",
       " 'nonneoplastic',\n",
       " 'specimens',\n",
       " 'dual-color',\n",
       " 'fluorescence',\n",
       " 'situ',\n",
       " 'hybridizations',\n",
       " 'using',\n",
       " 'paired',\n",
       " 'probes',\n",
       " 'cen9/p16',\n",
       " 'cen8/rb',\n",
       " 'cen17/p53',\n",
       " 'cen12/cdk4',\n",
       " 'performed',\n",
       " 'revealed',\n",
       " 'expected',\n",
       " 'frequencies',\n",
       " 'abnormalities',\n",
       " 'except',\n",
       " 'p53',\n",
       " 'losses',\n",
       " 'low',\n",
       " '7',\n",
       " 'latter',\n",
       " 'supports',\n",
       " 'concept',\n",
       " 'p53',\n",
       " 'inactivation',\n",
       " 'usually',\n",
       " 'occurs',\n",
       " 'mitotic',\n",
       " 'recombination',\n",
       " 'detected',\n",
       " 'abnormalities',\n",
       " 'p16/rb/cdk4',\n",
       " 'pathway',\n",
       " 'highly',\n",
       " 'associated',\n",
       " 'astrocytic',\n",
       " 'differentiation',\n",
       " 'univariately',\n",
       " 'associated',\n",
       " 'decreased',\n",
       " 'patient',\n",
       " 'survival',\n",
       " 'however',\n",
       " 'patient',\n",
       " 'age',\n",
       " 'histologic',\n",
       " 'classification',\n",
       " 'retained',\n",
       " 'statistical',\n",
       " 'significance',\n",
       " 'multivariate',\n",
       " 'analysis',\n",
       " 'conclude',\n",
       " 'diffuse',\n",
       " 'gliomas',\n",
       " 'p16/rb/cdk4',\n",
       " 'abnormalities',\n",
       " 'markers',\n",
       " 'astrocytic',\n",
       " 'phenotype',\n",
       " 'thus',\n",
       " 'detection',\n",
       " 'fluorescence',\n",
       " 'situ',\n",
       " 'hybridization',\n",
       " 'may',\n",
       " 'diagnostic',\n",
       " 'usefulness',\n",
       " 'cases',\n",
       " 'equivocal',\n",
       " 'morphologic',\n",
       " 'features',\n",
       " 'although',\n",
       " 'numbers',\n",
       " 'small',\n",
       " 'find',\n",
       " 'additional',\n",
       " 'prognostic',\n",
       " 'significance',\n",
       " 'genetic',\n",
       " 'abnormalities',\n",
       " 'one',\n",
       " 'age',\n",
       " 'grade',\n",
       " 'oligodendroglial',\n",
       " 'histology',\n",
       " 'taken',\n",
       " 'account',\n",
       " 'expression',\n",
       " 'mdm2/cdk4',\n",
       " 'gene',\n",
       " 'product',\n",
       " 'differential',\n",
       " 'diagnosis',\n",
       " 'well',\n",
       " 'differentiated',\n",
       " 'liposarcoma',\n",
       " 'large',\n",
       " 'deep-seated',\n",
       " 'lipoma',\n",
       " 'ordinary',\n",
       " 'lipomas',\n",
       " 'cytogenetically',\n",
       " 'characterized',\n",
       " 'variety',\n",
       " 'balanced',\n",
       " 'rearrangements',\n",
       " 'involving',\n",
       " 'chromosome',\n",
       " 'segment',\n",
       " '12q13-15',\n",
       " 'whereas',\n",
       " 'well',\n",
       " 'differentiated',\n",
       " 'liposarcomas',\n",
       " 'wdl',\n",
       " 'show',\n",
       " 'supernumerary',\n",
       " 'ring',\n",
       " 'giant',\n",
       " 'marker',\n",
       " 'chromosomes',\n",
       " 'known',\n",
       " 'contain',\n",
       " 'amplified',\n",
       " '12q',\n",
       " 'sequences',\n",
       " 'tight',\n",
       " 'correlation',\n",
       " 'presence',\n",
       " 'ring',\n",
       " 'chromosomes',\n",
       " 'amplification',\n",
       " 'overexpression',\n",
       " 'mdm2',\n",
       " 'cdk4',\n",
       " 'genes',\n",
       " 'suggests',\n",
       " 'exploration',\n",
       " 'possibility',\n",
       " 'immunocytochemistry',\n",
       " 'icc',\n",
       " 'might',\n",
       " 'assist',\n",
       " 'differential',\n",
       " 'diagnosis',\n",
       " 'lipoma-like',\n",
       " 'well',\n",
       " 'differentiated',\n",
       " 'liposarcomas',\n",
       " 'll-wdl',\n",
       " 'large',\n",
       " 'deep-seated',\n",
       " 'lipomas',\n",
       " 'ldsl',\n",
       " 'purpose',\n",
       " '21',\n",
       " 'cases',\n",
       " 'former',\n",
       " '19',\n",
       " 'cases',\n",
       " 'latter',\n",
       " 'tumours',\n",
       " 'analysed',\n",
       " 'icc',\n",
       " 'according',\n",
       " 'availability',\n",
       " 'material',\n",
       " 'molecular',\n",
       " 'cytogenetic',\n",
       " 'approaches',\n",
       " 'lipomas',\n",
       " 'displayed',\n",
       " 'null',\n",
       " 'mdm2/cdk4',\n",
       " 'phenotype',\n",
       " 'whereas',\n",
       " 'll-wdl',\n",
       " 'showed',\n",
       " 'mdm2/cdk4',\n",
       " 'cdk4',\n",
       " 'phenotypes',\n",
       " 'southern',\n",
       " 'blot',\n",
       " 'analysis',\n",
       " 'performed',\n",
       " '16',\n",
       " 'suitable',\n",
       " 'cases',\n",
       " 'complemented',\n",
       " 'fluorescence',\n",
       " 'situ',\n",
       " 'hybridization',\n",
       " 'classical',\n",
       " 'cytogenetic',\n",
       " 'analysis',\n",
       " '11',\n",
       " 'cases',\n",
       " 'consistent',\n",
       " 'supported',\n",
       " 'immunophenotyping',\n",
       " 'data',\n",
       " 'conclusion',\n",
       " 'mdm2/cdk4',\n",
       " 'product-based',\n",
       " 'immunophenotyping',\n",
       " 'appears',\n",
       " 'represent',\n",
       " 'valuable',\n",
       " 'method',\n",
       " 'categorization',\n",
       " 'arguable',\n",
       " 'ldsl',\n",
       " 'myxoid',\n",
       " 'liposarcoma',\n",
       " '12-year-old',\n",
       " 'girl',\n",
       " '12-year-old',\n",
       " 'girl',\n",
       " 'developed',\n",
       " 'myxoid',\n",
       " 'liposarcoma',\n",
       " 'inner',\n",
       " 'side',\n",
       " 'right',\n",
       " 'thigh',\n",
       " 'liposarcomas',\n",
       " 'extremely',\n",
       " 'rare',\n",
       " 'age',\n",
       " 'compared',\n",
       " 'benign',\n",
       " 'lipoblastomas',\n",
       " 'frequent',\n",
       " 'tumors',\n",
       " 'fatty',\n",
       " 'tissue',\n",
       " 'childhood',\n",
       " 'prognosis',\n",
       " 'myxoid',\n",
       " 'liposarcoma',\n",
       " 'good',\n",
       " 'especially',\n",
       " 'patient',\n",
       " 'tumor',\n",
       " 'located',\n",
       " 'subcutis',\n",
       " 'large',\n",
       " 'deep',\n",
       " 'excision',\n",
       " 'possible',\n",
       " 'often',\n",
       " 'curative',\n",
       " 'morphologic-cytogenetic',\n",
       " 'analysis',\n",
       " 'dedifferentiated',\n",
       " 'liposarcomas',\n",
       " 'extensive',\n",
       " 'misleading',\n",
       " 'leiomyosarcomatous',\n",
       " 'component',\n",
       " 'report',\n",
       " 'describes',\n",
       " 'two',\n",
       " 'cases',\n",
       " 'recurrent',\n",
       " 'retroperitoneal',\n",
       " 'dedifferentiated',\n",
       " 'liposarcoma',\n",
       " 'characterized',\n",
       " 'extensive',\n",
       " 'leiomyomatous',\n",
       " 'component',\n",
       " 'prevented',\n",
       " 'correct',\n",
       " 'diagnosis',\n",
       " 'last',\n",
       " 'recurrence',\n",
       " 'strong',\n",
       " 'immunoreactivity',\n",
       " 'smooth',\n",
       " 'muscle',\n",
       " 'desmin',\n",
       " 'antibodies',\n",
       " 'ultrastructural',\n",
       " 'features',\n",
       " 'consistent',\n",
       " 'leiomyosarcoma',\n",
       " 'observed',\n",
       " 'spindle-cell',\n",
       " 'and/or',\n",
       " 'myxoid-like',\n",
       " 'components',\n",
       " 'four',\n",
       " 'recurrences',\n",
       " 'case',\n",
       " '1',\n",
       " 'spindle-cell',\n",
       " 'component',\n",
       " 'primary',\n",
       " 'tumor',\n",
       " 'first',\n",
       " 'recurrence',\n",
       " 'case',\n",
       " '2.',\n",
       " 'case',\n",
       " '1',\n",
       " 'correct',\n",
       " 'diagnosis',\n",
       " 'suggested',\n",
       " 'cytogenetic',\n",
       " 'evidence',\n",
       " 'ring',\n",
       " 'markers',\n",
       " 'hallmark',\n",
       " 'well-differentiated/dedifferentiated',\n",
       " 'liposarcoma',\n",
       " 'case',\n",
       " '2',\n",
       " 'tumor',\n",
       " 'type',\n",
       " 'yielded',\n",
       " 'mainly',\n",
       " 'morphology',\n",
       " 'second',\n",
       " 'recurrence',\n",
       " 'consisted',\n",
       " 'entirely',\n",
       " 'well-differentiated',\n",
       " 'liposarcoma',\n",
       " 'sclerosing',\n",
       " 'inflammatory',\n",
       " 'variant',\n",
       " 'confirmed',\n",
       " 'karyotype',\n",
       " 'reevaluation',\n",
       " 'first',\n",
       " 'two',\n",
       " 'surgical',\n",
       " 'specimens',\n",
       " 'case',\n",
       " 'revealed',\n",
       " 'small',\n",
       " 'areas',\n",
       " 'consistent',\n",
       " 'well-differentiated',\n",
       " 'liposarcoma',\n",
       " 'previously',\n",
       " 'overlooked',\n",
       " 'despite',\n",
       " 'smooth-muscle',\n",
       " 'antigen',\n",
       " 'profile',\n",
       " 'cases',\n",
       " 'retained',\n",
       " 'mdm2+/p53+/cdk4+',\n",
       " 'immunophenotype',\n",
       " 'consistent',\n",
       " 'genotype',\n",
       " 'dedifferentiation',\n",
       " 'well-differentiated',\n",
       " 'liposarcoma',\n",
       " 'highly',\n",
       " 'malignant',\n",
       " 'metastatic',\n",
       " 'osteosarcoma',\n",
       " 'amplification',\n",
       " '12q14',\n",
       " 'stages',\n",
       " 'gain',\n",
       " '1q22-q24',\n",
       " 'associated',\n",
       " 'metastases',\n",
       " 'well-differentiated',\n",
       " 'liposarcomas',\n",
       " 'wdlps',\n",
       " 'especially',\n",
       " 'located',\n",
       " 'retroperitoneum',\n",
       " 'may',\n",
       " 'occasionally',\n",
       " 'undergo',\n",
       " 'dedifferentiation',\n",
       " 'although',\n",
       " 'process',\n",
       " 'associated',\n",
       " 'aggressive',\n",
       " 'clinical',\n",
       " 'course',\n",
       " 'dedifferentiated',\n",
       " 'liposarcomas',\n",
       " 'rarely',\n",
       " 'produces',\n",
       " 'metastases',\n",
       " 'case',\n",
       " 'reported',\n",
       " 'rather',\n",
       " 'uncommon',\n",
       " 'retroperitoneal',\n",
       " 'wdlps',\n",
       " 'gave',\n",
       " 'lung',\n",
       " 'metastases',\n",
       " 'diagnosed',\n",
       " 'highly',\n",
       " 'malignant',\n",
       " 'osteosarcomas',\n",
       " 'used',\n",
       " 'comparative',\n",
       " 'genomic',\n",
       " 'hybridization',\n",
       " 'cgh',\n",
       " 'fluorescence',\n",
       " 'situ',\n",
       " 'hybridization',\n",
       " 'fish',\n",
       " 'southern',\n",
       " 'blot',\n",
       " 'analyses',\n",
       " 'characterize',\n",
       " 'copy',\n",
       " 'number',\n",
       " 'changes',\n",
       " 'genetic',\n",
       " 'aberrations',\n",
       " 'occurring',\n",
       " 'different',\n",
       " 'stages',\n",
       " 'disease',\n",
       " 'primary',\n",
       " 'tumor',\n",
       " 'detectable',\n",
       " 'aberration',\n",
       " 'amplification',\n",
       " '12q13-q14',\n",
       " 'present',\n",
       " 'fraction',\n",
       " 'cells',\n",
       " 'revealed',\n",
       " 'fish',\n",
       " 'analysis',\n",
       " 'high-level',\n",
       " 'amplification',\n",
       " '12q13-q14',\n",
       " 'involving',\n",
       " 'cdk4',\n",
       " 'mdm2',\n",
       " 'hmgic',\n",
       " 'seen',\n",
       " 'relapse',\n",
       " 'metastases',\n",
       " 'second',\n",
       " 'common',\n",
       " 'change',\n",
       " 'gain',\n",
       " 'high-level',\n",
       " 'amplification',\n",
       " '1q22-q24',\n",
       " 'detectable',\n",
       " 'cgh',\n",
       " 'osteogenic',\n",
       " 'metastases',\n",
       " 'loss',\n",
       " 'distal',\n",
       " '2q',\n",
       " 'fish',\n",
       " 'analyses',\n",
       " 'revealed',\n",
       " 'considerable',\n",
       " 'heterogeneity',\n",
       " 'samples',\n",
       " 'percentage',\n",
       " 'cells',\n",
       " ...]"
      ]
     },
     "execution_count": 93,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "nltk.download('punkt')\n",
    "\n",
    "# Convert the data to lower case \n",
    "PM_abstract_title = pmSet['title'].str.lower() + ' ' + pmSet['abstract'].str.lower()\n",
    "\n",
    "\n",
    "# Removed stop words and punctuations\n",
    "PM_no_stopWords = []\n",
    "for text in PM_abstract_title:\n",
    "    words = word_tokenize(text)\n",
    "    for word in words:\n",
    "        if word not in stopwords.words('english') and word not in string.punctuation:\n",
    "            PM_no_stopWords.append(word)\n",
    "\n",
    "PM_no_stopWords"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 288,
   "metadata": {},
   "outputs": [],
   "source": [
    "# filter the stopwords from title\n",
    "text3 = text2\n",
    "text3 = ' '.join([word for word in text3.split() if word not in (stopwords.words('english'))])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 289,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "0 Cancer pancreas. Palliative operation, Whipple procedure, total pancreatectomy? 1 Rauwolfia derivatives breast cancer hypertensive women. 2 Repeated light- electron microscopic studies small-bowel mucosa Whipple's disease. 3 alpha-Lactalbumin human subhuman primate normal mammary tissue human breast cancer marker prolactin activity. 4 Dynamics neoplastic development carcinogen-exposed tracheal mucosa. 5 [Some epidemiological factors incidence female genital cancer Azerbaijan SSR]. 6 Role hypertension ischemic heart disease cerebral vascular disease cynomolgus monkey coarctation aorta. 7 [Pancreatic diseases]. 8 Infant human pancreas. A potential source islet tissue transplantation. 9 The many faces islet cell tumors. 10 Analysis human tumors human malignant cell lines BK virus-specific DNA sequences. 11 [Insulinoma]. 12 [Nesidioblastoma]. 13 Aetiology breast cancer: brief review. 14 Adjuvant systemic therapy lung cancer. 15 Twelve year old caucasian male asymptomatic hypertension. 16 Antitrypsin chronic obstructive pulmonary disease among Japanese-American men. 17 [Pancreatic reticulosarcoma 12-year-old boy]. 18 Reactivity monoclonal anti-melanoma antibodies melanoma cells freshly isolated primary metastatic melanoma. 19 Transcendental meditation heterohypnosis altered states consciousness. 20 Electrocardiographic changes adriamycin chemotherapy. 21 Probable parasellar meningioma pregnant woman. 22 Hemorrhage retinoschisis diagnosed malignant melanoma. 23 Fine-needle aspiration biopsy ampullary pancreatic carcinoma. 24 [Role colonoscopy diagnosis treatment large bowel disease]. 25 Renal metastasis adenocarcinoma lung: massive hematuria managed therapeutic embolization. 26 Computed tomographic staging malignant gastric neoplasms. 27 Necrolytic migratory erythema, presenting candidiasis, due pancreatic glucagonoma. 28 Histopathology evaluation total pancreatectomy ductal carcinoma. 29 [Prevention cervical cancer detection therapy carcinoma situ]. ... 18687 Vinorelbine plus cisplatin versus gefitinib resected non-small cell lung cancer haboring activating EGFR mutation (WJOG6410L). 18688 Safety efficacy MET inhibitor tivantinib (ARQ 197) combined sorafenib patients (pts) NRAS wild-type mutant melanoma phase I study. 18689 Prognostic significance KRAS BRAF mutations Japanese patients colorectal cancer. 18690 Thymidylate synthase (TS) gene expression patients ALK positive (+) non-small cell lung cancer (NSCLC): Implications therapy. 18691 Phase II study multikinase inhibitor dovitinib (TKI258) placebo combination fulvestrant postmenopausal, endocrine resistant HER2-/HR+ breast cancer. 18692 FGFR1 amplification EGFR mutation Chinese squamous cell lung cancer. 18693 ALK MET genes advanced lung adenocarcinomas: The Lung Cancer Mutation Consortium experience. 18694 A phase I dose-escalation study HSP90 inhibitor AUY922 erlotinib patients EGFR-mutant lung cancer acquired resistance (AR) EGFR tyrosine kinase inhibitors (EGFR TKIs). 18695 EGFR-TKI benefit NSCLC patients EML4-ALK rearrangement. 18696 Different EGFR/KRAS mutation spectrums lung cancer never smokers heavy smokers. 18697 A static diagnostic biopsy patients mutated EGFR lung adenocarcinom guide therapeutic decisions. 18698 Frequency clinical characterization NSCLC patients harboring PIK3CA mutations identified within regional screening network. 18699 Amplification fibroblast growth factor receptor type 1 gene (FGFR1) samples 101 NSCLC patients (pts) squamous cell carcinoma (SCC) histology. 18700 Clinical characteristics natural history patients squamous cell lung carcinoma FGFR1 amplification. 18701 Higher incidence EGFR exon 19 deletion younger (age 40 younger) patients adenocarcinoma lung. 18702 Tumor PIK3CA mutations, lymphocyte infiltration, recurrence-free survival (RFS) early breast cancer (BC): Results FinHER trial. 18703 Long-term survivors advanced nonsquamous non-small cell lung cancer (nsNSCLC) treated first-line (1L) chemotherapy (CT) plus bevacizumab (B) maintenance (mtc) B. 18704 Utility novel quantitative EGFR-mutated protein analysis using AQUA system EGFR-TKI treatment non-small cell lung cancer. 18705 KIF5B-RET: Discovery novel fusion oncogene lung adenocarcinomas systematic screen tyrosine kinase fusions identification patients RET targeted therapy trial. 18706 Incidence prognostic impact KRAS BRAF mutations patients undergoing liver surgery colorectal metastases. 18707 Use carboplatinum neoadjuvant setting patients affected locally advanced cervical cancer. 18708 ALK amplification crizotinib sensitivity non-small cell lung cancer cell lines patients report. 18709 Proliferation pathway aberration frequencies BRCA1- BRCA2-mutated ovarian cancers. 18710 Analysis KRAS BRAF mutant colorectal cancers multiracial population. 18711 Sensitivity refractory hairy cell leukemia BRAF inhibition. 18712 Review current status KRAS mutation testing France 2011: The Flash-KRAS study. 18713 Highly sensitive determination PIK3CA exon 9 20 hotspot mutations breast tumors. 18714 Ethnic difference driver mutation frequencies correlations driver mutations histologic subtypes lung adenocarcinoma. 18715 Prevalence low-penetrance KRAS (codons 12/13 61) BRAF mutations metastatic colorectal carcinoma. 18716 Multiplex testing driver mutations squamous cell carcinomas lung. Name: title, Length: 18717, dtype: object\n"
     ]
    }
   ],
   "source": [
    "# filter the stopwords from abstract\n",
    "text4 = text1\n",
    "text4 = ' '.join([word for word in text4.split() if word not in (stopwords.words('english'))])\n",
    "print(text4)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 290,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[\"0 Cancer pancreas. Palliative operation, Whipple procedure, total pancreatectomy? 1 Rauwolfia derivatives breast cancer hypertensive women. 2 Repeated light- electron microscopic studies small-bowel mucosa Whipple's disease. 3 alpha-Lactalbumin human subhuman primate normal mammary tissue human breast cancer marker prolactin activity. 4 Dynamics neoplastic development carcinogen-exposed tracheal mucosa. 5 [Some epidemiological factors incidence female genital cancer Azerbaijan SSR]. 6 Role hypertension ischemic heart disease cerebral vascular disease cynomolgus monkey coarctation aorta. 7 [Pancreatic diseases]. 8 Infant human pancreas. A potential source islet tissue transplantation. 9 The many faces islet cell tumors. 10 Analysis human tumors human malignant cell lines BK virus-specific DNA sequences. 11 [Insulinoma]. 12 [Nesidioblastoma]. 13 Aetiology breast cancer: brief review. 14 Adjuvant systemic therapy lung cancer. 15 Twelve year old caucasian male asymptomatic hypertension. 16 Antitrypsin chronic obstructive pulmonary disease among Japanese-American men. 17 [Pancreatic reticulosarcoma 12-year-old boy]. 18 Reactivity monoclonal anti-melanoma antibodies melanoma cells freshly isolated primary metastatic melanoma. 19 Transcendental meditation heterohypnosis altered states consciousness. 20 Electrocardiographic changes adriamycin chemotherapy. 21 Probable parasellar meningioma pregnant woman. 22 Hemorrhage retinoschisis diagnosed malignant melanoma. 23 Fine-needle aspiration biopsy ampullary pancreatic carcinoma. 24 [Role colonoscopy diagnosis treatment large bowel disease]. 25 Renal metastasis adenocarcinoma lung: massive hematuria managed therapeutic embolization. 26 Computed tomographic staging malignant gastric neoplasms. 27 Necrolytic migratory erythema, presenting candidiasis, due pancreatic glucagonoma. 28 Histopathology evaluation total pancreatectomy ductal carcinoma. 29 [Prevention cervical cancer detection therapy carcinoma situ]. ... 18687 Vinorelbine plus cisplatin versus gefitinib resected non-small cell lung cancer haboring activating EGFR mutation (WJOG6410L). 18688 Safety efficacy MET inhibitor tivantinib (ARQ 197) combined sorafenib patients (pts) NRAS wild-type mutant melanoma phase I study. 18689 Prognostic significance KRAS BRAF mutations Japanese patients colorectal cancer. 18690 Thymidylate synthase (TS) gene expression patients ALK positive (+) non-small cell lung cancer (NSCLC): Implications therapy. 18691 Phase II study multikinase inhibitor dovitinib (TKI258) placebo combination fulvestrant postmenopausal, endocrine resistant HER2-/HR+ breast cancer. 18692 FGFR1 amplification EGFR mutation Chinese squamous cell lung cancer. 18693 ALK MET genes advanced lung adenocarcinomas: The Lung Cancer Mutation Consortium experience. 18694 A phase I dose-escalation study HSP90 inhibitor AUY922 erlotinib patients EGFR-mutant lung cancer acquired resistance (AR) EGFR tyrosine kinase inhibitors (EGFR TKIs). 18695 EGFR-TKI benefit NSCLC patients EML4-ALK rearrangement. 18696 Different EGFR/KRAS mutation spectrums lung cancer never smokers heavy smokers. 18697 A static diagnostic biopsy patients mutated EGFR lung adenocarcinom guide therapeutic decisions. 18698 Frequency clinical characterization NSCLC patients harboring PIK3CA mutations identified within regional screening network. 18699 Amplification fibroblast growth factor receptor type 1 gene (FGFR1) samples 101 NSCLC patients (pts) squamous cell carcinoma (SCC) histology. 18700 Clinical characteristics natural history patients squamous cell lung carcinoma FGFR1 amplification. 18701 Higher incidence EGFR exon 19 deletion younger (age 40 younger) patients adenocarcinoma lung. 18702 Tumor PIK3CA mutations, lymphocyte infiltration, recurrence-free survival (RFS) early breast cancer (BC): Results FinHER trial. 18703 Long-term survivors advanced nonsquamous non-small cell lung cancer (nsNSCLC) treated first-line (1L) chemotherapy (CT) plus bevacizumab (B) maintenance (mtc) B. 18704 Utility novel quantitative EGFR-mutated protein analysis using AQUA system EGFR-TKI treatment non-small cell lung cancer. 18705 KIF5B-RET: Discovery novel fusion oncogene lung adenocarcinomas systematic screen tyrosine kinase fusions identification patients RET targeted therapy trial. 18706 Incidence prognostic impact KRAS BRAF mutations patients undergoing liver surgery colorectal metastases. 18707 Use carboplatinum neoadjuvant setting patients affected locally advanced cervical cancer. 18708 ALK amplification crizotinib sensitivity non-small cell lung cancer cell lines patients report. 18709 Proliferation pathway aberration frequencies BRCA1- BRCA2-mutated ovarian cancers. 18710 Analysis KRAS BRAF mutant colorectal cancers multiracial population. 18711 Sensitivity refractory hairy cell leukemia BRAF inhibition. 18712 Review current status KRAS mutation testing France 2011: The Flash-KRAS study. 18713 Highly sensitive determination PIK3CA exon 9 20 hotspot mutations breast tumors. 18714 Ethnic difference driver mutation frequencies correlations driver mutations histologic subtypes lung adenocarcinoma. 18715 Prevalence low-penetrance KRAS (codons 12/13 61) BRAF mutations metastatic colorectal carcinoma. 18716 Multiplex testing driver mutations squamous cell carcinomas lung. Name: title, Length: 18717, dtype: object\", '0 The choice operation ductal carcinoma pancreas yet clear. Failure make early diagnosis still stands major problem treatment disease result resectability rate exceedingly low. Between 1964 1973, nineteen total pancreatectomies performed Peter Bent Brigham Hospital tumors pancreas. Sixteen ductal carcinoma. The mortality 12.5 per cent. When total pancreatectomy compared Whipple procedure simple bypass procedure tumor disease encountered corrected stage disease, apparent total pancreatectomy carries statistically significant longer survival patients Stages I II disease (no lymph node involvement) two procedures. For Stages III IV, difference survival three different operations. We therefore conclude total pancreatectomy carries better survival prognosis procedures performed Stage I II ductal carcinoma pancreas. 1 Three groups women selected sample death certificates coded Office Population Censuses Surveys conditions mentioned them: (1) women reference breast cancer hypertension; (2) women reference hypertension cancers; (3) group women reference hypertension without cancer, selected match breast-cancer patients respect five features. When women breast cancer compared women cancers women without cancer, positive association breast cancer use rauwolfia derivatives, although neither differences frequency duration observed statistically significant. The association appeared strongest use near time diagnosis cancer. This agrees nearly data would expected rauwolfia derivatives promoted development breast cancer previously initiated cells. 2 The small-bowel mucosa patient Whipple\\'s disease florid state one year starting antibiotic treatment, complete clinical remission examined author. As result treatment, light-microscopic changes led total regression. Electronmicroscopically, florid state, destruction small-bowel epithelial cells observed, mostly Lieberk√ºhn\\'s crypts. The changes epithelial cells regressed one year treatment. In lamina propria, large amount macrophages containing characteristic inclusions found persisted even treatment. The composition inclusions has, however, changed. The macrophages cells poor organelles primitive differentiation. Presumably, morphological picture associated digestion incapability cells may lead development \"acquired storage disease\". 3 NaN 4 NaN 5 In structure cancer morbidity female genitalia Azerbaijan SSR within ten-year period (1957-1966) cervical cancer occupies first place--86.6%, observed frequently among Russian female population (46.4 per 100 000 wives) rarely among aboriginal female population (7.1 per 100 000 wives). Of 2488 patients cervical cancer 24.5% showed previous lesions background cancer would arise. Patients cervical ruptures, advanced erosions, polyps identified high-risk groups cervical cancer. 6 The role hypertension cardiovascular disease studied hypertensive coarcted monkey feeding atherogenic nonatherogenic diet. During 15-month period observation, half hypertensive coarcted monkeys developed cardiovascular disease included heart failure, ischemic heart disease, stroke, sudden death. There cardiovascular complications control normotensive monkeys except one cholesterol-fed animal. The incidence ischemic heart disease sudden cardiac death higher monkeys hypertension hypercholesterolemia hypertension hypercholesterolemia alone. Postmortem studies revealed former monkeys hypertensive atherosclerotic heart disease, whereas monkeys hypertension hypercholesterolemia either hypertensive atherosclerotic heart disease. Hypertensive heart disease characterized hypertrophy left ventricle also focal myocardial degeneration fibrosis focal thickening narrowing small coronary arteries, particularly sinus node artery atrioventricular node artery. The finding transmural myocardial infarction two monkeys patient coronary arteries suggests possible role coronary artery spasm ischemic heart disease hypertension. The cerebral vascular complications hypertension included hypertensive encephalopathy, transient \"ischemic\" attacks, hemorrhagic stroke. The complications associated severe hypertension hypertensive vascular disease hypertensive atherosclerotic vascular disease cerebral arteries. 7 NaN 8 Twelve pancreases human infants one year old less analyzed tissue insulin amylase content dispersal pancreatic fragments mincing collagenase digestion. Tissue insulin amylase content provide index pancreatic islet mass exocrine digestive enzyme content, respectively. The results compared similar anaylses performed juvenile adult human pancreases islet isolation intact dispersed neonatal rat adult rat pancreas. Infant human pancreas average tissue insulin concentration 1,128 mug./gm. tissue total insulin content 1,718 mug/pancreas, values 140 mug./gm. tissue 7,209 mug./pancreas adult human pancreas. Average tissue amylase concentration 0.24 mg./gm. tissue infant human pancreas 3.0 mg./gm. tissue adult human pancreas. The insulin/amylase ratio infant pancreas 4,800, 46 adult pancreas. Neonatal rat pancreas, dissociated transplanted without separation islet exocrine components, similarly high tissue insulin low tissue amylase content compared adult rat pancreases. Infant human pancreas total islet mass 24 per cent adult human pancreas, neonatal rat pancreas total islet mass 11 per cent adult rat pancreas. One neonatal rat pancreas prepared minimal collagenase digestion cure diabetes transplanted via portal vein rat. Following dispersal infant human pancreas collagenase digestion, islet content insulin/amylase ratio recovered tissue equals exceeds usually isolated adult cadaver pancreases. Infant human pancreas rich source islet tissue relatively uncontaminated exocrine digestive enzymes. After dispersal, infant human pancreas may ideal transplantation selected diabetic patients. 9 NaN 10 Most humans United States infected BK virus (BKV), human papovavirus. Because BKV oncogenic properties, investigated whether may cause human cancer. Basic principles tumor virology imply BKV-induced tumors contain BKV DNA sequences. Therefore, assayed (by molecular hybridization) DNA human tumors malignant cell lines BKV DNA, using BKV [(32)P]DNA probe. The BKV [(32)P]DNA labeled vitro (nick translation) specific activities 1 2 x 10(8) cpm/mug. The BKV DNA used prepare probes properties expected authentic BKV genomes, including density superhelical DNA, sedimentation velocity alkaline neutral sucrose gradients, production one fragment endonuclease EcoRI cleavage four fragments endonuclease Hin II + III cleavage reassociation properties. From studies conclude BKV probes hybridized well, represented bona fide BKV DNA. Using three different BKV [(32)P]DNA probes, i.e., three distinct plaque isolates, analyzed DNA BKV-transformed cells, normal human tissues, large number human tumors. All human DNAs (cell lines, normal tissues, tumors) hybridized 5% BKV DNA. Hybridization analysis BKV-transformed hamster cell DNA indicated 5-6 copies least 88% BKV genome per cell. No BKV DNA sequences detected (above normal 5% hybridization human DNAs) following normal human tissues: 10 kidney (BKV usually isolated urine), 3 spleen, 13 lung, 23 colon, 2 rectum, 1 ileum, 1 skin. No BKV-specific DNA found 166 tumors, including 5 carcinomas (Ca) stomach, 3 Ca small intestine, 26 Ca colon, 9 Ca rectum, 31 Ca lung, 9 adenocarcinomas 5 oat cell carcinomas lung, 17 melanomas, 5 Ca prostate, 4 Ca bladder, 6 Wilms tumors, 4 hypernephromas, 15 Ca kidney, 7 brain tumors, 5 Hodgkin lymphomas, 10 lymphomas (immunosuppressed patients high incidence lymphomas), 2 reticulum cell sarcomas (spleen), 3 skin tumors. We also analyzed 7 human malignant cell lines (melanoma, lung, rhabdomyosarcoma, glioblastomas), including several clones lung melanoma line; BKV DNA sequences detected. Because probes could detect one copy BKV DNA 10% cells tumor cells, results strong evidence tumors analyzed BKV etiology. The tumors tested represent 50% cancers United States; evidence BKV involved etiology types tumors. 11 NaN 12 NaN 13 Cancer human breast probably group diseases different causes. Changes hormonal status increase breast cancer risk probably \\'promoting\\' tumour development rather \\'initiating\\' it. Exogenous oestrogens seem act tumour promoters context, date evidence oral contraceptives, contain oestrogens low dosage, increase breast cancer risk. On contrary, appear reduce incidence benign breast tumours. Prolactin-release associated increased mammary tumour incidence rats humans. There evidence viruses exposure hair-dyes increase breast cancer risk. The fact slight dietary restriction dramatically reduce mammary tumour incidence rats, suggests dietary factors looked closely search aetiological factors man. 14 Most patients lung cancer subjected surgical resection likely residual tumor burdens lead clinical relapse death. Unfortunately, none systemic therapies squamous cell, large cell adenocarcinoma lung demonstrated curative potential either advanced disease surgical adjuvant setting. Interest clinical trials adjuvant therapy lung cancer rekindled three factors: 1) reports indicating value immunotherapy, 2) preliminary encouraging experience new chemotherapy programs, 3) methodologies including stage- cell type-specific clinical trials leading better interpretation results. These concepts stimulated new treatment protocol studies within NCI-sponsored Lung Cancer Study Group, clinical cooperative groups. 15 NaN 16 A total 161 patients chronic obstructive pulmonary disease (COPD) plus 100 control subjects (identified study heart disease 6,860 Japanese-American men aged 52 75 years residing Hawaii) analyzed phenotype search antitrypsin gene Z, shown associated pulmonary emphysema racial groups. No carriers Z gene found, question whether rarity absence gene relates low frequency COPD among Japanese-Americans reviewed. 17 NaN 18 Human melanoma cells, freshly obtained nine primary metastatic melanoma cases, tested binding monoclonal anti-melanoma antibodies produced vitro hybridoma clones. Monoclonal anti-melanoma antibodies bind melanoma cells react nonmalignant cells obtained patients cells obtained giant hairy nevus. These results confirm existence tumor-specific antigens. Binding monoclonal antibodies melanoma cells several origins, primary metastatic, different patients suggests existence tumor antigens shared human melanoma cells. The binding pattern different antibodies various cells also predicts existence one tumor-specific antigenic determinant melanoma cells. 19 NaN 20 The electrocardiograms 146 patients metastatic carcinoma breast reviewed before, during, patients received Adriamycin (Doxorubicin) chemotherapy (AD). The significant electrocardiographic change occurred amplitude QRS voltage. Seven patients developed cardiomyopathy AD showed significant decrease QRS voltage. This decrease, however, severe onset congestive heart failure conclusion Adriamycin. In 35 patients pleural effusion, inverse relation extent effusion amplitude QRS voltage absence congestive heart failure. These results indicate 1) sudden relatively severe decrease QRS voltage onset CHF limits value ECG criterion predicting early Adriamycin toxicity, 2) caution exercised interpretation QRS voltage changes patients significant pleural effusion. 21 An intracranial meningioma diagnosed 28-year-old woman second trimester fifth pregnancy. Similar cases literature reviewed experience Thomas Jefferson University Hospital intracranial neoplasms occurring pregnant woman 10-year period January 1965 January 1976 reported. The management reported patient pathophysiology meningiomas discussed. 22 A 55-year-old man organized hemorrhage retinoschisis simulated malignant melanoma clinically ultrasonography. The correct diagnosis made histopathologically enucleation. 23 Cytological verification angiographic, sonographic, and/or intraoperative diagnosis pancreatic ampullary carcinoma may achieved fine-needle aspiration biopsy (FNAB). Fifteen biopsies done 13 patients, 12 thought pancreatic carcinoma clinically. The FNAB specimen confirmed 11 them. Also, one equivocal (suspicious), two false-negative, false-positive results recorded. Complications seen. In addition, four patients ampullary carcinoma pancreatoduodenectomy basis FNAB specimens. Since method accurate safer simpler traditional wedge core biopsy suspected pancreatic ampullary tumors, since may eliminate need laparotomy selected cases, consider preferred method immediate diagnosis neoplasms. 24 NaN 25 The rare complication massive hematuria secondary metastatic infiltrating adenocarcinoma lung kidney managed steel coil therapeutic embolization. The angiographic pathologic picture well advantages therapeutic modality clinical setting discussed. 26 Eight patients proved gastric carcinoma 3 gastric lymphoma studied preoperatively computed tomography. CT accurately identified abnormal stomach wall thickening intra-abdominal tumor extension. Mural thickening seen CT scan moderately distended stomach wall 10 mm thick. CT useful assessing surgical resectability, evaluating tumor response chemotherapy radiotherapy, detecting postoperative recurrence. Fourteen patients abnormal barium study suggesting gastric malignancy also studied CT, correctly demonstrated normal stomach identified reason abnormal barium study, unusual placed spleen pancreatic carcinoma invading stomach. 27 A 54-year-old male diabetes, weight loss, glossitis Candidiasis presented typical cutaneous eruption necrolytic migratory erythema. The suspicion pancreatic glucagonoma confirmed elevated plasma glucagon level. Surgical removal pancreatic alpha cell tumor resulted complete disappearance symptoms. The importance recognition skin eruption necrolytic migratory erythema clue presence pancreatic glucagonoma emphasized. 28 Whipple resections pancreatic head carcinoma often inadequate tumor left behind body tail. Thirty-six patients undergone total pancreatectomy various conditions, 25 undergone total pancreatectomy, ductal carcinoma. Thirty-seven per cent 25 patients shown histologic evidence Whipple resection would adequately removed tumor-bearing pancreatic tissue. Three patients carcinoma spreading along common bile duct primary ductal carcinoma head pancreas. Four patients tumor infiltrating continuity pancreatic body tail distance palpable tumore head well left Whipple transection site. Five patients widespread multifocal autonomous tumor involving areas gland tumor palpable head pancreas. Three patients (12%) died postoperatively. The two year survival rate 32%, five year survival, 19%. Histological factors affecting survival prognosis include 1) positive nodes, 2) tumor extension common duct, 3) intrapancreatic extension multicentricity tumor mandating total pancreatectomy hope cure least 38% cases. 29 NaN ... 18687 Background: Vinorelbine plus cisplatin completely resected stage II-III non-small cell lung cancer (NSCLC) standard therapy. Stage IV non-small cell lung cancer (NSCLC) harboring mutations epidermal growth factor receptor (EGFR) quite sensitive tyrosine kinase inhibitors (TKIs). Three randomized trials demonstrated gefitinib superior platinum based chemotherapy progression free survival. Retrospective analysis adjuvant TKIs therapy patient resected lung cancer harboring EGFR mutation showed favorable trend toward improvement disease free survival (DFS) overall survival (OS). (J Thorac Oncol. 2011;6: 569575) BR19 comparing adjuvant gefitinib vs. placebo completely resected NSCLC without selection biomarker closed early show benefit adjuvant gefitinib, even EGFR mutation positive cohort. The randomized trial adjuvant therapy erlotinib vs. placebo patients overexpression EGFR protein complete enrolment already. We conduct first randomized phase III trial comparing adjuvant gefitinib chemotherapy patients completely resected stage II-III NSCLC harboring EGFR mutations. Methods: Patients undergone complete resection EGFR mutation, deletions exon 19, L858R point mutation exon 21 without T790M mutation randomly assigned gefitinib 250mg day 2 years vinorelbine 25mg/m2 days 1 8, plus cisplatin 80mg/m2 day 1, every 3 weeks 4 courses. The primary endpoint DFS secondary endpoints OS safety. On basis previous studies, assume hazard ratio DFS 0.65. To demonstrate improvement DFS, 230 patients total would needed 3-year accrual period. This trial begun September 12 among 22 institutes Japan. Until (January 31. 2012), 13 cases enrolled. Five cases enrolled latest 1 month. 18688 Background: The MET receptor tyrosine kinase implicated tumor cell proliferation, invasion, metastasis, activated NRAS mutant melanoma. Tivantinib oral, selective MET inhibitor currently phase II/III clinical trials. Tivantinib plus sorafenib exhibited synergistic antitumor activity vs single-agent activity several tumor models. This phase I dose-escalation study assessed safety tivantinib plus sorafenib pts advanced solid tumors. Methods: Endpoints safety, recommended phase II dose (RP2D) tivantinib plus sorafenib, antitumor activity. Dose escalation previously established RP2D tivantinib 360 mg twice daily (BID) plus sorafenib 400 mg BID. Extension cohorts enrolled 20 pts melanoma tumors. Pts treated disease progression unacceptable toxicity. Results: 16 pts melanoma (median age, 66 yr) received treatment RP2D, 3 pts still study. 12 pts received 1 previous systemic anticancer treatment (median, 1.2; range, 0-5) including ipilimumab (2 pts) MEK inhibitor (1 pt). Common adverse events ( 25%) rash (50%), diarrhea fatigue (44% each), anorexia (38%), stomatitis nausea (31% each), anemia, weight decrease, hypophosphatemia (25% each). Best responses complete response (CR) 1 pt, partial response (PR) 3 pts, stable disease (SD) 3 pts. 4 pts progressive disease 5 pts evaluable (3 pts reached first assessment time, 1 pt withdrew consent, 1 pt unacceptable toxicity). The overall response rate disease control rate 25% 44%, respectively. Median progression-free survival (mPFS) 5.3 mo (95% CI, 1.6-12.9 mo). Among 8 pts NRAS mutations, mPFS 9.2 mo (95% CI, 5.3-12.9 mo) responses 1 CR, 1 PR, 2 SD. Conclusions: Tivantinib plus sorafenib combination therapy well tolerated exhibited preliminary anticancer activity pts melanoma. Dual inhibition MET angiogenesis may effective treatment strategy NRAS-mutant melanoma. 18689 Background: Recent evidence highlights potential prognostic predictive value BRAF K-RAS gene alterations patients colorectal cancer. To determine whether differences exist molecular mechanisms driving colorectal cancer Japanese Western, characterized Japanese patients colorectal cancer assessing genetic alterations involved cancer progression response treatment. Methods: We retrospectively evaluated 254 Japanese diagnosed colorectal cancer institution 1994 2009. Mutations KRAS codons 12 13 BRAF codon 600 identified direct sequencing. Microsatellite instability (MSI) status determined genotyping 5 loci. Associations KRAS BRAF mutation clinicopathological characteristics prognosis evaluated. Results: KRAS BRAF mutation detected 33.5% 6.7% patients, respectively. KRAS mutation correlated poor recurrence free survival (RFS) (p = 0.03), especially stage II patients (p = 0.007). BRAF mutation significantly correlated anatomical site tumor (p < 0.001), tumor grade (p = 0.001) high frequency microsatellite instability (p < 0.001). BRAF mutation also correlated poor overall survival cases patients (p = 0.009). Overall, background KRAS BRAF mutation almost similar CRCs Western countries Japanese. However, KRAS mutation status considered helpful predict recurrence Japanese patients stage II CRC. Conclusions: Our findings indicate BRAF K-RAS mutation plays important role tumorigenesis colorectal cancer. These results indicate molecular analysis BRAF K-RAS may useful biomarker identifying patients right-sided colon cancer poor outcome may benefit individualized course therapy. 18690 Background: ALK+ NSCLC represents molecular target-defined patient population highly responsive ALK inhibitor crizotinib. Previous reports also suggested increased sensitivity ALK+ NSCLC chemotherapeutic agent pemetrexed. Thymidylate synthase (TS) candidate predictive biomarker pemetrexed activity. Here report analysis Response Genetics Inc. (RGI) database association implications therapy. Methods: ALK fusion identified novel RT-PCR assay (Danenberg et al: ASCO 2010). For TS, RNA microdissected formalin-fixed paraffin-embedded tumors analyzed previously described, reported ratio gene expression -actin. For reference, TS level <2.33 cutpoint sensitivity. Results: TS levels available 63 ALK+ patients 1,698 ALK- control lung adenocarcinoma patients. All ALK+ patients adenocarcinomas without EGFR KRAS mutations. Median age: 59.0 (range 33-88), gender (male/female) 32/31 (51%/49%). Median TS RNA level ALK+ patients 2.02, range (0.55-19.44), ALK- patients 3.32 (0.36-53.51), p<0.0001 (Mann-Whitney test). The majority ALK+ patients (N=43, 68%) TS level <2.33 cutpoint, compared 32% ALK- patients (N=551, p<0.0001). Conclusions: This analysis demonstrates relatively low TS gene expression ALK+ patient tumors determined RT-PCR. These data provide mechanism action supportive pemetrexed sensitivity ALK+ NSCLC. TS expression N Median 95% CI Range Mean 95% CI p value ALK+ patients 63 2.02 1.60-2.11 0.55-19.44 2.53 1.89-3.16 <0.0001 ALK- patients 1698 3.32 3.15-3.45 0.36-53.51 7.87 1.68-14.05 18691 Background: Overcoming endocrine resistance critical goal treatment hormone receptorpositive (HR+) breast cancer. Molecular mechanisms associated endocrine resistance include adaptive cross-talk estrogen receptor fibroblast growth factor receptor (FGFR). Up 8% HR+/HER2- breast cancer patients (pts) amplification FGFR1 gene, associated resistance endocrine therapy overcome via FGFR1 inhibition preclinical models. Dovitinib potent FGF, VEGF, PDGF receptor tyrosine kinase inhibitor demonstrated antitumor activity heavily pretreated breast cancer pts FGF pathway amplification (FGFR1, FGFR2, ligand FGF3; Andre et al, ASCO 2011). Dovitinib may reverse resistance endocrine therapy related FGF-pathway amplification studied determine improve outcomes combined fulvestrant. Methods: Postmenopausal HER2-/HR+ locally advanced metastatic breast cancer pts (N150) progressing within 12 months completion adjuvant endocrine therapy 1 prior endocrine therapy advanced setting enrolled multicenter, randomized, double blind, placebo controlled, phase II trial. Pts prospectively undergo molecular screening enrich FGF-amplification (FGFR1, FGFR2, FGF3 amplification qPCR; 45 amplified 30 non-amplified pts per arm). Pts randomized 1:1 receive fulvestrant (500 mg q4w [with additional dose 2 wks initial dose]) combination oral dovitinib (500 mg, 5 days on/2 days off) placebo disease progression, unacceptable toxicity, death. The primary endpoint progression-free survival, tumor assessments performed q8w. Secondary endpoints include overall response rate per RECIST v1.1, duration response, overall survival, ECOG performance status patient reported outcome scores time, safety. The pharmacodynamic effect dovitinib FGFR-associated angiogenic pathways tumor specimens potential predictive biomarkers response dovitinib explored. 18692 Background: Squamous cell lung cancer (SCC) lacks effective targeted therapies. FGFR1 amplification emerged potential biomarker. This study aimed explore clinicopathologic characteristics FGFR1 amplification Chinese SCC patients explore correlation FGFR1 amplification EGFR mutations. Methods: One hundred seventy-seven SCC patients included retrospective study. Gene copy number FGFR1 EGFR mutations detected fluorescence situ hybridization (FISH) denaturing high-performance liquid chromatography (DHPLC), respectively. Results: FGFR1 amplifications detected 24.9% (44/177) Chinese SCC patients. FGFR1 amplification SCC common male (28.0%, 40/143) smokers (28.7%, 39/136) female (11.8%, 4/34, p=0.049) nonsmokers (12.2%, 5/41, p=0.032). FGFR1 amplification EGFR mutations mutually exclusive (p=0.006), fourty-one 139(29.4%) patients wild-type EGFR FGFR1 amplification, 3 38 (7.9%) patients EGFR mutation FGFR1 amplification. Conclusions: FGFR1 amplification common Chinese squamous cell lung cancer, mutually exclusive EGFR mutations. 18693 Background: The Lung Cancer Mutation Consortium (LCMC) consisting 14 US Cancer Centers established evaluate panel molecular mutations advanced lung adenocarcinoma. ALK gene fusions MET gene amplification assessed FISH CLIA certified laboratories. Methods: Molecular tests performed stage IIIB IV lung adenocarcinoma. To date, FISH assays completed 901 patients ALK (ALK break-apart, Abbott Molecular) 654 patients MET (in house/Abbott Molecular reagents). ALK+ specimens defined split 3ALK/5ALK signals (gap >2 signal diameters) single 3ALK signals >15% tumor cells. MET gene amplification (MET+) defined ratio mean MET/mean CEP7 2. Results: The ALK+ patient subset (N=75, 8.3%) compared ALK- significantly lower age diagnosis (52 vs. 60, p<0.001) less frequent heavy smoking history (61% never-smokers among ALK+ vs. 31% among ALK-, p<0.001; pack-year current/former smokers 17 vs. 40, p=0.003). Liver metastases significantly frequent among ALK+ ALK- (23% vs.10%, p=0.004); difference detected bone, brain adrenal gland metastases. MET+ (N=29, 4.4%) significantly associated female sex (72% female among MET+ vs. 39% among MET-, p<0.001) marginally frequent patients adrenal metastasis; difference detected age diagnosis smoking history. Follow-up 73 ALK+ patients indicated 56% received crizotinib targeted therapy. Response unknown 8% unreportable 22% patients enrolled ongoing randomized trials. Among patients evaluable response, complete response, partial response, stable disease, progressive disease found respectively 3%, 66%, 28%, 3%. Conclusions: The LCMC successfully tested ALK MET FISH large number lung adenocarcinomas. It demonstrated directing positive patients specific interventions feasible, grouping testing trials within consortia may maximise relevant trial accrual rare molecular subtypes. Supported NCI-GO award. Submitted behalf LCMC. 18694 Background: AUY922 highly potent, non-geldanamycin analog, HSP90 inhibitor degrades mutated EGFR MET. Preclinical studies demonstrate HSP90 inhibitors anti-tumor activity EGFR mutant, EGFR TKI-sensitive TKI-resistant lung cancer xenograft models. To prevent disease flare stopping EGFR TKIs patients (pts) EGFR mutated lung cancer, erlotinib (E) often continued subsequent lines treatment AR. This phase I study determine maximally tolerated dose (MTD) AUY922 E pts mutated EGFR RECIST progression EGFR TKIs. Methods: All pts EGFR mutant lung cancer, development AR (per Jackman, JCO 2010) treatment EGFR TKI. Pts underwent repeat tumor biopsies development AR prior study entry. Pts receive AUY922 IV weekly E oral daily 28-day cycles, dose escalation using standard 3+3 design. Pharmacokinetics, serial ophthalmology evaluations weekly assessment toxicity required. Tumor tissue re-biopsy study entry analyzed EGFR T790M MET. Results: Since April 2011, 11 pts enrolled, 4 5 planned cohorts (AUY922 25 mg/m2 + E 75 mg; AUY922 25 mg/m2+ E 150 mg; AUY922 37.5 mg/m2+ E 150 mg; AUY922 55 mg/m2+E 150 mg). Prior developing AR, pts treated EGFR TKIs median 9 months (range 8-32). Of 9 pts tissue analyzed thus far, 6 EGFR T790M. Pts received median two cycles (range 1-7), 5 remain study. There dose-limiting toxicities. Adverse events reported 20% pts diarrhea, nausea, vomiting, fatigue, rash, graded 1 2. No cardiovascular, renal hepatic toxicities observed. Three pts reported flashing lights 2 pts transient night blindness, grade 1. Dose escalation continues. No partial responses seen 6 evaluable pts, 4 patients confirmed stable disease 8 wks. Conclusions: AUY922 E well-tolerated combination dose levels AUY922 55 mg/m2+ E 150 mg. Further dose-escalation, MTD, correlation markers AR reported. Supported Novartis, Inc. 18695 Background: EML4-ALK rearrangement defines new molecular subtype non-small-cell lung cancer (NSCLC). To identify biological profiles patients, examined clinico-pathologic characteristics treatment outcomes NSCLC patients based EML4-ALK EGFR mutations. Methods: Patients stage IV NSCLC screened EML4-ALK rearrangement EGFR mutations Peking University Cancer Hospital. EML4-ALK identified using fluorescent situ hybridization (FISH) confirmed immunohistochemistry (IHC), EGFR mutations determined using denaturing high-performance liquid chromatography (DHPLC). Results: Of 151 patients screened, 113 complete follow-up data analysis set. The incidence EML4-ALK 9.7% (11/113) using FISH, 10 cases sufficient specimens IHC confirmation positive. Overall, EML4-ALK EGFR mutations largely mutually exclusive (p = 0.033), although two patients harbored concurrent mutations. EML4-ALK rearrangement associated resistance EGFR-TKIs compared EGFR mutant type WT/Nonrearrangement type (p = 0.001 objective response rate; p = 0.004 disease control rate; p = 0.021 progression-free survival [PFS]). In terms patients received platinum-based doublet chemotherapy, significant differences observed PFS EML4-ALK type, EGFR mutant type, WT/Nonrearrangement type. Moreover, two patients concurrent EML4-ALK EGFR mutations superior PFS EGFR-TKI compared single EML4-ALK-rearranged patients. Conclusions: This study presents several biological features EML4-ALK NSCLC. It largely mutually exclusive EGFR mutations, resistant EGFR-TKI. Coexistence ALK rearrangement EGFR mutation patients advanced NSCLC might represent separate genotype unique biological characteristics. 18696 Background: EGFR mutations commonly found lung adenocarcinomas never smokers, KRAS mutations frequently present heavy smokers. Although incidence low, EGFR mutations also found tumors heavy smokers KRAS mutations also occur tumors never smokers. Therefore, may different biological characteristics EGFR/ KRAS mutated lung cancers according smoking status. Methods: This retrospective review 382 patients surgically resected lung cancers February 2009 March 2011. The clinicopathological factors (age, gender, histology, serum CEA level, pathological nodal status, lymphatic permeation, blood vessel invasion) EGFR/KRAS mutation spectrums compared never smokers (pack-year = 0, n = 161) heavy smokers (pack-year > 20, n = 167). Results: EGFR mutations detected 88 (55%) never smokers 33 (20%) heavy smokers. In contrast, K-ras mutations detected 7 (4%) never smokers 31 (19%) heavy smokers. Both EGFR KRAS mutations frequently observed female never smokers male heavy smokers. The spectrum EGFR KRAS mutation differed according smoking status. Minor EGFR mutations exon 21 L858R exon 19 deletions activating mutations indicating efficacy EGFR tyrosine kinase inhibitors (TKIs) frequently found heavy smokers never smokers. GA transitions common KRAS mutations never smokers GT transversions thought related exposure polycyclic aromatic hydrocarbons found cigarette smoke common KRAS mutations heavy smokers. Conclusions: The EGFR/KRAS mutation spectrums lung cancer quite different never smokers heavy smokers. Further study needed evaluate relationship efficacy molecular targeting agents EGFR TKIs EGFR/KRAS mutation spectrums. 18697 Background: Approximately 70% pts. whose lung cancers harbor EGFR mutations acquire drug resistence response EGFR tyrosine kinase inhibitors (TKIs) treatment; acquired resistance mainly due secondary mutation EGFR (T790 M) 50% patients, amplification MET 15%, PIK3CA mutations 5%, unknown mechanism almost 30%, SCLC transformation patients. Furthermore, clinical experience revealed cancers acquired resistance respond TKIs, drug-free interval. To aid identification treatment patients examined cohort patients whose cancers assessed tumor biopsies multiple times treatment TKIs. Methods: 21 lung adenocarcinomas pts. (10 male, 11 female, median age 53 years) EGFR mutations 19 21 exons received TKIs, first line treatment. All showed clinical response relapsed ( mTTP 10 months). At time relapse new biopsy performed, histologic samples reviewed re-confirm diagnosis, EGFR MET amplification identified FISH, EGFR mutations tested DNA sequencing. Results: At time drug resistence acquired pts. retained original activating EGFR mutations, 9 pts. developed EGFR T790M resistance mutation pronunced EGFR amplification 3, 2 pts. developed MET amplification, 8 biopsies reveal new mutations, two pts. found diagnosis small cell lung cancer drug resistant tumor biopsies responded well conventional chemotherapy regimen.15 19 confirmed lung adenocarcinoma patient underwent cisplatin - pemetrexed chemotherapy regimen time progression 10 accepted undergo new biopsy. Three pts. ( 4, 5 6 months break treatment TKIs ) lost T790M mutation disease responded second-line course erlotinib. Conclusions: In cohort pts. acquired EGFR resistence patients lost acquired T790M mutation become sensitive EGFR inhibitor, addition, two pts. underwent histologic transformation NSCLC SCLC time TKI resistence. 18698 Background: PIK3CA mutations rare oncogenic event potential therapeutic relevance NSCLC. Here report frequency characteristics patients PIK3CA mutated lung tumors. Methods: Patients NSCLC PIK3CA mutations identified within regional Network Molecular Screening Lung Cancer. We analyzed presence BRAF, KRAS, EGFR mutations well ALK translocation, ERBB2 FGFR1 amplifications PIK3CA mutated samples. Clinical data age, sex, TNM classification tumor stage, histological type, grading, overall survival, smoking status, comorbidity, BMI secondary malignancies retrieved clinical charts accordance local ethics committee. Results: PIK3CA mutations detected frequency 3.7% (24% exon 20,76% exon 9) 1000 patients. Histologically 32% defined squamous cell carcinoma, 48% adenocarcinoma 18% histological subtypes NSCLC-NOS. Exon 9 mutations present acinar lepidic subtype, whereas exon 20 mutations seen papillary solid subtype. Cooccuring genetic lesions observed 16% (mutations KRAS=2, EGFR=1, BRAF=1; FGFR1 amplification=2). 14 female, 23 male mean age 69 years. 21 patients clinically annotated. 11 patients presented stage IIIb/IV eligible palliative treatment 10 stage I IIIa eligible surgical therapy +/- adjuvant therapy. All 1 patient smokers average BMI 26,2kg/m2 typical high load comorbidity mainly cardiovascular diseases, 8 21 patients showed prior malignancies medical history. The median overall survival within population reached yet. Conclusions: Screening PIK3CA mutations feasible. A high proportion (38%) patients PIK3CA mutated lung cancer prior malignancies show high load comorbidity. Furthermore PIK3CA mutations exclusive KRAS, EGFR BRAF mutations FGFR1 amplifications. Successful identification patients oncogenic lesions lung cancer screening network might allow future personalized treatment patients. 18699 Background: The FGFR1 gene located chromosomal region 8p12 encodes transmembrane receptor tyrosine kinase. Amplification FGFR1 reported lung cancer, predominantly SCC (in ~ 20%) considered potential target treatment anti-FGFR1 agents. Different methods cutoff levels determine FGFR1 amplification reported yet consensus reached standard method. The aim study assess FGFR1 amplification determined FISH analysis set samples 101SCC pts explore clinical features. Methods: Tumor samples 101SCC pts diagnosed institution August 2007 August 2011 screened FGFR1 amplification FISH using ZytoLight SPEC FGFR1/CEN8 probe. FGFR1 considered FISH positive ratio > 2.2 FISH FGFR1 polysomic 3 signals 30% tumor cells, result considered negative. For exploratory analyses FGFR1 amplification considered positive median 6 gene copies identified FISH polysomic 2 gene copies less 6. Results: Pts characteristics: median age 76 yrs (range 45-80), 91% male, 33% current smokers, 67% former smokers, stage: 8% IA/ 15% IB/ 11% IIA/ 11% IIB/ 24% IIIA, 12% IIIB/ 19% IV. With median follow 48 months, median overall survival 18 months. FISH FGFR1 positive (ratio > 2.2) 7 (6.9%) pts: 6 male, 4 former smokers. FISH FGFR1 considered negative polysomic (3 signals 30% tumor cells) 43/94 (45%) pts. If use FISH positivity cutoff 6 copies 3 patients considered positive FGFR1 amplification (2 also FISH positive ratio>2.2). All 5 patients considered FISH negative gen copy number (but positive ratio) polysomic. Conclusions: In experience FGFR1 amplification detected FISH isrelatively uncommon SCC, although relevant proportion FGFR1 FISH negative tumors polysomy. Standarization methods determine FGFR1 amplification potential clinical significance presence FGFR1 polysomy needed. 18700 Background: FGFR1 amplifications described promising oncogenic target squamous cell lung cancer. Here aimed describing clinical characteristics natural history FGFR1amplified squamous cell lung cancer patients. Methods: From 01/2011 01/2012 screened 553 squamous cell lung cancer patients Network Molecular Screening Lung Cancer presence FGFR1 amplifications FISH analysis accordance local ethics committee. FGFR1 defined amplified ratio FGFR1 copies centromeric copies 2 50% tumor cells showed 5 copies 15% tumor cells demonstrated clusters FGFR1. Clinical data collected extracting information medical records, local cancer registry questioning treating physicians patients. Results: FGFR1FISH analysis could performed 95% cases amplified 16%. Of amplified cases 75 % male 25% female without significant enrichment male female. The median age patients diagnosis 67 yrs (range 46 - 82). Stage presentation was: 16% I; 17.3% II; 26.7% IIIa, 40% IIIb/IV. 97,3% patients former active smokers median 40 pack years. The median progression free survival patients stage IIIb/IV disease 11 months (95% CI 8-14; n=14). The median overall survival yet reached median follow-up time 14 months (95% CI 11 - 17; n=24). We screened co-existing genetic lesions mutations EGFR, BRAF, KRAS, PIK3CA well translocations ALK amplifications ERBB2. Two patients demonstrated co-occurring PIK3CA mutations one BRAFmutation. Conclusions: Screening FGFR1 feasible routine clinical conditions. By implementation regional molecular screening network ability screen FGFR1 amplification successfully expanded non-academic centers private practices. FGFR1 amplifications squamous cell cancer lung frequent (16%) associated smoking history. Screening FGFR1 might pave way application new FGFR1 directed targeted drugs squamous cell lung cancer. 18701 Background: The proportion younger patients ( 40 years) lung cancer reported 2-5%. The frequent histologic type adenocarcinoma, however little known pathological molecular characteristics younger patients lung adenocarcinoma. Methods: Between July 1992 April 2011, total 7443 patients diagnosed lung cancer National Cancer Center Hospital East 165 patients (2.2%) 40 years younger identified. Among them, 44 patients adenocarcinoma underwent surgical resection selected study. In addition, 185 elderly patients > 40 years underwent surgical resection matching gender smoking status selected control group. Histological predominant growth pattern coexisting variant pattern, status EGFR mutations compared two groups. Results: The median age 40 years patients 37 years (range, 21 40 years) elderly patients 68 years (range, 42 83 years). Between two groups, significant differences distribution histological predominant growth patterns (lepidic; 31.8% vs. 26.5%, papillary; 34.1% vs. 37.3%, acinar; 9.1% vs. 16.2%, solid; 25.0% vs. 20.0%, p=0.78) incidence EGFR mutations (40.9% vs. 45.9%; p=0.55). However, signet-ring cell component significantly found younger patients elderly (11.4% vs. 0%; p<0.01). The incidence EGFR exon 19 deletion significantly higher younger patients elderly, contrast, EGFR exon 21 L858R significantly higher elderly patients (exon 19 del; 31.7% vs. 18.9%, L858R; 4.6% vs. 25.4%, p=0.0091). Three 17 adenocarcinomas (17.7%) EGFR-wild type younger patients showed positive ALK translocation. Conclusions: Younger patients lung adenocarcinoma showed significantly higher proportion EGFR exon 19 deletion genotype containing histologically signet-ring cell component comparing elderly patients. EGFR exon 19 deletion genotype may related pathogenesis lung adenocarcinoma younger patients. 18702 Background: Tumor PIK3CA mutations (mts) lymphocyte infiltration (LI) prognostic BC, importance unknown HER2-positive (HER2+) BC treated adjuvant trastuzumab (T). Methods: The FinHER trial randomized 1010 patients (pts) pN+ high-risk pN- BC 3 cycles docetaxel (D) vinorelbine, followed 3 cycles FEC. Pts HER2+ BC randomized 9 weeks T T (n=232). Pts treated D T superior outcome prior analyses. BC samples subjected somatic hotspot mt profiling (Sequenom) quantification percentage tumor LI using full-face H&E sections. RFS interactions T explored Kaplan-Meier Cox regression analyses. Results: The median FU time 62 months. 935 (92.6%) 687 (68.1%) tumors underwent LI mt analysis, respectively. Correlation LI assessment 2 pathologists 0.78 (p<0.001). 54 mts detected 13 genes evaluated. PIK3CA mts (exons 1,2,9,13,18,20) present 25.3% (n=174) ERBB2 mt 4.5% (n=31) BCs. Only 1 AKT mt found none KRAS, BRAF, NRAS PTEN. In ER+/HER2-, HER2+ ER-/HER2- subtypes prevalence PIK3CA mts 30.2%, 19.5% 9.2%; ERBB2 mt 6.3%, 1.9% 2.6%, respectively (both p<0.05). Neither PIK3CA ERBB2 mts associated RFS overall within BC subgroups. No interaction found benefit T presence PIK3CA mt HER2+ BC (interaction p=0.17 T vs T). Increasing LI associated favorable RFS ER-/HER2- BC (continuous score adjusted p=0.032); 3-y RFS 90% extensive LI (>30% infiltrated) vs 66% non-extensive LI (p=0.007). In HER2+ BC, whilst association prognosis overall, significant interaction benefit T vs. T increasing LI (continuous score interaction p=0.042) 3-yr RFS 96% vs 78% extensive non-extensive LI treated T respectively (p=0.014). Conclusions: We report 3 clinically relevant findings large clinical trial dataset: 1) PIK3CA mts prognostic; 2) LI strong prognostic factor ER-/HER2- BC 3) first time extensive LI predicts benefit adjuvant T. 18703 Background: B plus CT followed mtc B shown improve outcomes patients (pts) nsNSCLC. In clinical setting, pts able receive prolonged mtc treatment (Tx) B. The aim research explore clinical characteristics, order assess behavior pts benefit B. Methods: In 30 Spanish institutions studied retrospectively data 104 pts advanced nsNSCLC receiving long-time mtc B defined PFS 9 months (m), represents increase PFS approximately 50%, compared historical data. Clinical histological characteristics, Tx received, ORR, median PFS OS, safety data recorded. Results: Pts characteristics: median age 57 years (yr); caucasian: 98%; ECOG PS 0/1/2 (%): 61/38/2; male: 61%; current/former/never smokers (%): 36/45/19; baseline hypertension (HTN)/cardiovascular disease (%): 24/9; adenocarcinoma: 82%; stage IV: 84%; 84% pts presented 2 metastatic sites; central tumor location: 30%; tumor cavitation: 4%; among 40 pts tested, 8% presented activating EGFR mutations. 1L CT was: carboplatin/cisplatin doublets (%): 57/43; median no. cycles CT/B mtc B 6 18, respectively. Median B dose 7.5 mg/kg. ORR: 83%. Of 71% pts evidence PD 1L, 90% received second-line (2L) Tx. 77% pts progressed 2L, received third-line (3L). B maintained 26% 24% pts receiving 2L 3L. Median PFS: 15 (CI 95%:14-16); median OS: 31 (95% CI: 22-39). 1 2 yrs survival rates (%): 97 (95% CI: 93 - 100) 62 (95% CI: 51 - 73). Most frequent B related toxicities (%): gr 1/2 epistaxis (22/0), gr 1/2 HTN (12/6), grade 1/2/3 asthenia (2/6/4) gr 1/2/3 proteinuria (3/3/1). Conclusions: To knowledge, first data reported long-term survivors advanced nsNSCLC treated 1L CT/B plus long-time mtc B. Although prospective evaluation required, outstanding median OS (31 m) 2-yr survival (62%) point importance selecting Tx role mtc B 1LB. B well tolerated, without significant life-threatening toxicities. Subgroup analyses presented. 18704 Background: Lung cancer carrying EGFR mutation (muEGFR) expresses good response EGFR tyrosine kinase inhibitors (TKIs). However, patients (pts) mutation showed similar clinical benefits EGFR-TKIs. Heterogeneity tumor cells considered one plausible reason. MuEGFR usually genotyped qualitative manner present clinical practice. In addition, new technology AQUA system enables us measure protein levels objectively considering expression heterogeneity tissues. Here investigated correlation AQUA score obtained specimen response response duration EGFR-TKIs. Methods: Slice sections genotyped 105 pts muEGFR 33 pts wild-type EGFR stained E746-A750 deletion (6B6)- L858R (43B2)-specific antibodies. Homo- heterogeneous staining muEGFR protein levels specimens evaluated AQUA system. Results: Concordance rate genotypes AQUA-based phenotypes (deletion L858R), cut-off values based ROC curve, 60% 82%. Low sensitivity 6B6 due lucking reactivity deletion variants. Alternatively, specificities antibodies 96% 92%, indicating highly selectivity muEGFR protein. The AQUA score 27 pts treated EGFR-TKIs varied (8.7 907.4) falls plot analysis indicated pts high AQUA score showed better objective response. Specimens partial response (PR) significantly higher AQUA score progression disease (136.5 vs 9.8, p=0.014). When divided pts two groups based median AQUA score, pts high AQUA score showed tendency longer treatment duration (21 mo vs 14 mo, p=0.162). These results indicate AQUA-based analysis classify pts carrying genotyped muEGFR susceptible less susceptible ones EGFR-TKIs. Conclusions: We observed pts high AQUA score sensitive EGFR-TKIs. It important predicting sensitivity EGFR-TKIs investigate genotyping also muEGFR protein levels using AQUA system. 18705 Background: The mutually exclusive pattern major targetable driver oncogenes lung adenocarcinomas (ADC) suggests similar driver oncogenes may exist. We therefore performed systematic screen tyrosine kinase (TK) fusions cases without known driver oncogenes measuring aberrantly high RNA expression kinase domain (KD) exons relative 5 exons. Methods: We studied 74 patients whose lung ADC lacked mutations KRAS, EGFR, BRAF, HER2, ALK fusions. A NanoString-based assay designed query transcripts 90 TKs two points: 5 KD within 3 KD. Tumor RNAs hybridized NanoString probes analyzed outlier 3 5 expression ratios. The assay validated samples known ALK ROS fusions. Presumed novel fusion events followed rapid amplification cDNA ends (RACE) confirmatory RT-PCR. Results: The NanoString assay identified aberrant 5 3 ratios ROS RET 2 cases, respectively, 74. RACE analysis isolated novel GOPC-ROS fusion former novel KIF5B-RET fusion latter, confirmed RT-PCR. Further screening RT-PCR KIF5B-RET identified one positive sample study set detected NanoString. At RNA level, fusions joined exon 15 KIF5B exon 12 RET, thus retaining portion dimerization domain KIF5B entire KD RET, analogous RET fusions papillary thyroid carcinoma (TC). One KIF5B-RET patient 60 y.o. female never smoker, other, 73 y.o. male former smoker. Conclusions: The novel KIF5B-RET fusion described also recently reported Ju YS et al. (Genome Res, Dec 22, 2011) defines new subset lung ADC potentially targetable driver oncogene. Based genetic data preclinical activity RET inhibitor XL184 (Exelixis) papillary TC known activity medullary TC RET mutations, initiated prospective testing KIF5B-RET part lung ADC screening panel anticipation planned phase 2 trial XL184 patients KIF5B-RET related variant RET fusions. 18706 Background: Molecular biomarkers offer potential refining prognostic determinants patients undergoing cancer surgery. Among patients colorectal cancer metastases, KRAS BRAF important biomarkers, role patients undergoing surgical therapy liver metastases unknown. In study, prevalence prognostic significance KRAS BRAF mutations determined patients undergoing surgical therapy colorectal liver metastases (CRLM). Methods: KRAS BRAF analysis performed 202 patients undergoing curative intent surgical therapy CRLM 2003 2008. Tumor samples analyzed somatic mutations using sequencing analysis (KRAS: codon 12/13, BRAF: V600E). The frequency mutations ascertained impact outcome determined relative clinicopathologic factors. Results: KRAS gene mutations detected 58/202 patients (29%) undergoing surgery CRLM, comparable reported non-surgical patient series. In contrast, mutation BRAF gene identified low frequency surgical cohort, found 4/202 (2%) patients. KRAS mutations associated worse long-term survival (HR=2.13, CI=1.25-3.65), well risk recurrence (HR=1.89, CI=1.12-3.19). ). In addition, KRAS mutation also associated risk recurrence following surgical therapy (HR=1.89, CI=1.12-3.19).While clinicopathologic features, including tumor number, CEA primary stage also associated survival, KRAS status remained independently predictive outcome. The low incidence BRAF mutation limited ability determine prognostic impact. Conclusions: While KRAS mutations found approximately one third patients, BRAF mutations found 2% patients undergoing surgery CRLM. KRAS status independent predictor overall disease-free survival. Molecular biomarkers KRAS may help refine prognostic assessment patients undergoing surgical therapy CRLM. 18707 Background: The aim study evaluate efficacy safety combination carboplatin paclitaxel neoadjuvant chemotherapy (NACT) patients affected locally advanced cervical cancer. Methods: Between June 2007 May 2009, patients diagnosis IB2-IIB cervical cancer considered eligible protocol. All enrolled patients received 3 cycles carboplatin (AUC6) paclitaxel 175 mg/mq neadjuvant setting. The chemotherapy induced toxicity response treatment evaluated according World Health Organization criteria. Results: We enrolled 23 patients diagnosis locally advanced cervical cancer. A total 22 patients completed planned 3 cycles neoadjuvant chemotherapy. After 3 cycles chemotherapy 9 23 patients (42%) showed complete response, 7 patients (35%) partial response, 5 patients (16%) stable disease 2 patients (11%) showed disease progression. The common toxicity haematologic (43%), extra haematologic toxicities nausea/vomiting, neuropathy alopecia, occurred 45%, 13% 25% respectively. No renal grade 3 4 haematologic toxicities registered. Conclusions: Our results suggest use carboplatin, neadjuvant setting, well tolerated drug, produces manageable toxicity response rate similar standard cisplatin. Then, rappresents valid alternative patients affected locally advanced cervical cancer. 18708 Background: ALK high copy number (HCN) seems frequent event, described 13-17% Non-small cell lung cancer (NSCLC). The goal study describe ALK genomic aberrations NSCLC patients cell lines, explore ALK HCN response crizotinib vitro assays report three patients case. Methods: 191 Paraffin embedded specimens advanced NSCLC patients 27 NSCLC cancer cell lines screened ALK copy number fluorescent situ hybridization (FISH). Crizotinib sensitivity evaluated 9 cell lines WST1 assays clonogenic tests. Three patients exhibiting ALK HCN assessed response crizotinib. Results: EML4-ALK translocation present 22 pts (11.5%). 21 pts (11%) exhibited 6 copies ALK. 6 (22%) cell lines displayed 5 copies ALK, 19 (70%) presented gain 3 4 ALK copy number, one cell line exhibited normal ALK copies one harbored EML4-ALK translocation. FISH CEP2 revealed polysomy chromosome 2 cases ALK HCN.Out 9 cell lines tested, 4 ALK HCN cell lines (H661, A427, BEN, H1299) exhibited increased sensitivity crizotinib vs. 3 low ALK copy number (LCN) cell lines (H1975, H1651, H1650) low sensitivity. Median IC50 crizotinib values was1750 nM [300-2800nM] ALK HCN cell lines vs 4500 nM [800-8000nM] ALK LCN cell lines, p=0.35. 3 patients ALK HCN tumor received crizotinib ( 4th , 5th 6th -line therapy) 2, 3 5 months stable disease best response clinical benefit 2 pts. Conclusions: ALK HCN may predict sensitivity crizotinib. A clinical study planned ALK HCN pts. 18709 Background: Large-scale genomic analyses high-grade, advanced-stage serous ovarian cancers The Cancer Genome Atlas (TCGA) project revealed aberrations genes comprising key proliferation survival pathways (RB-E2F, RAS, PI3K) majority tumors. Patients germline BRCA1/2-mutations favorable prognoses non-BRCA carriers, recent work suggests BRCA2 carriers better BRCA1. We hypothesized concurrent proliferation pathway aberrations BRCA1/2 mutations tumors might play role patient outcome. Methods: Mutation, copy number, clinical data 309 TCGA-profiled serous ovarian tumors downloaded MSKCC cBIO web portal. Each tumor scored aberrant pathway gene (RB: RB1, CDKN2A, CCND1, CCND2, E2F3, CCNE1; PI3K: PIK3CA, PTEN, AKT1, AKT2; RAS: KRAS, BRAF, NF1) pathway mutated, amplified, deleted. Results: 205 309 tumors aberration least one pathways. The frequency pathway alteration differed significantly BRCA1 (82%, 28/34), BRCA2 (52%, 17/33) BRCA1/2 WT (66%, 160/242) tumors (BRCA1 vs. BRCA2: Fishers p= 0.0096). BRCA1 tumors frequently contained alterations multiple pathways BRCA2 WT tumors (41% vs. 24% 25%, respectively). RB-E2F pathway alteration frequency significantly different (BRCA1: 56%, BRCA2: 18%, WT: 43%, p=0.0043), significant differences PI3K RAS pathway aberration frequencies (BRCA1%: 41, 38; BRCA2%: 36, 27; WT% 28, 27), respectively, observed. In agreement previous report, BRCA2 patients significantly better overall survival (OS) either BRCA1 WT patients (median OS months BRCA1: 35.9, BRCA2 45.4, BRCA1/2 WT 27.8; p=0.001). Presence pathway alterations significantly associated OS BRCA1, BRCA2, WT patients cohort. Conclusions: These results show negative association BRCA2 mutations aberrations key proliferation survival pathways. Beyond BRCA1 BRCA2 genetic mutations, elevated frequency pathway alteration BRCA1 vs. BRCA2 tumors highlights differences may important patient prognosis well therapy responses. 18710 Background: We previously demonstrated racial disparities colorectal cancer (CRC) survival despite adjustments tumor socioeconomic factors. Molecular differences breast lung tumors contribute racial survival inequality, yet CRC, molecular tumor characteristics studied extensively racially diverse cohort. We performed comprehensive evaluation KRAS BRAF mutations multiracial population determine prevalence CRC degree molecular traits impact survival. Methods: A retrospective cohort study patients diagnosed CRC 2008 2011 hospital tumor registries performed. The prevalence KRAS BRAF mutations determined study population individual racial groups. Multivariable Cox proportional hazards regression models survival built KRAS BRAF mutation status adjusting age diagnosis, race, stage disease. Results: Of 706 patients diagnosed CRC, KRAS mutational analysis performed 148 subjects. 14% subjects white (W), 64% Asian (A), 21% Native Hawaiian/Pacific Islander (NH). KRAS mutation identified 48 subjects (32%). The prevalence mutant tumors among racial groups W 33%, A 36%, NH 30%. Analysis KRAS G13D mutations revealed prevalence W 11%, A 9%, NH 7%. When compared published datasets predominantly white patients, multiracial cohort significantly higher rate KRAS G13D mutant tumors, p=0.039. Of 74 subjects tested BRAF mutation, two mutant tumors detected (3%). The prevalence BRAF mutation race 10% W, 3% A, 0% NH (p=0.18). BRAF KRAS G13D mutations adverse prognostic factors multivariate analysis, although odds ratios failed meet statistical significance. Conclusions: The prevalence BRAF KRAS mutations multiracial cohort similar previously reported. However rates KRAS G13D BRAF mutant tumors cohort higher prior reports. Furthermore, KRAS G13D postulated favorable prognostic factor CRC, may adversely impact survival minority patients. 18711 Background: Thorough understanding genetic lesions cancer targeted intervention driver mutations beginning transform cancer treatment. An activating mutation BRAF serine/threonine protein kinase, BRAF V600E occurs proportion malignant melanomas, colorectal, thyroid, cancers. In hairy-cell leukemia (HCL), BRAF V600E nearly always present, suggesting oncogene dependence. Methods: Here, present patient HCL refractory three lines purine analogue-based treatment. The BRAF V600E mutation demonstrated. After intensive counseling, patient family provided written consent vemurafenib (mutant BRAF-specific inhibitor) treatment. Results: Before vemurafenib treatment, patient subtotal bone marrow infiltration massive splenomegaly (24.8 x 8.3 cm) leading severe cytopenia (leukocytes 680/l, hemoglobin 10.0 g/dl, platelets 36.000/l). Treatment vemurafenib started 240 mg twice daily slowly escalated 1920 mg/d. Within two days treatment, spleen softened decreased size. Serum CD25 (sCD25) level fell rapidly 24.800 U/ml normal levels (<900), platelets, hemoglobin, leukocyte counts rose. After 16 days vemurafenib treatment, spleen size shrunk 14 x 5 cm. By day 28 treatment (on 720 mg/d), platelet counts sCD25 levels normalized. Bone marrow infiltration HCL decreased 70% 20% day 16 complete remission achieved day 35. We terminated treatment day 57 evidence circulating hairy cells immunophenotyping. Conclusions: The striking therapeutic activity vemurafenib patient provides first vivo evidence substantiate BRAF V600E allele driver validates mutant BRAF therapeutic target HCL. Proof principle molecularly targeted therapy HCL adds recent success targeting oncogenic kinases oncogene addicted malignancies. Given rarity HCL, introducing new therapeutic modalities may challenging. Future studies needed compare short-term inhibition BRAF low doses vemurafenib (or alternative BRAF inhibitors) standard therapy. 18712 Background: KRAS testing required treatment initiation cetuximab management metastatic colorectal cancer (mCRC). The objective study examine current situation 2011 regarding KRAS testing initial management mCRC. Methods: This observational, retrospective, national study carried March 28th April 8th 2011. During period 538 patients mCRC included across 160 french hospitals. The main objective assess rate KRAS testing patients started first line (L1) treatment mCRC. The secondary objectives describe time taken techniques used KRAS testing, possible reasons test requested, describe analyse clinical characteristics patients planned L1 treatments finally received. Results: KRAS testing carried 433 patients (81.1%) carried 101 patients (18.9%). The main reasons requesting KRAS status (several answers possible): anti-EGFR prescribed (n=58), candidate surgery (n=8), samples useable (n=5), age patient (n=3), (n=24), data missing (n=13). The genotyping results available mean delay 23.6 28.2 days. The KRAS testing requested oncologist (45.5%), gastroenterologist (31%), surgeon (11.2%), pathologist (7.2%) multidisciplinary group (5.1%) approximately 15 days (-66.5;33.6) median (min ; max) diagnosis metastases, 15 days (-66.9;3.7) median (min ; max) start L1 treatment. Result KRAS status received L1 treatment chosen 56.6% patients. For patients wild-type KRAS status whose therapeutic management modified result KRAS testing (n=108), change prescription anti-EGFR 77.8% cases. Conclusions: The Flash-KRAS study first one assess current modalities KRAS genotyping France. It shows 2011 KRAS test integral part management patients mCRC. Nonetheless, shows disparities regions terms time obtain results, need improved compatible therapeutic management. 18713 Background: Hotspot mutations exons 9 (E542K E545K) 20 (H1047L H1047R) PIK3CA gene encoding p110 catalytic subunit Phosphatidylinositol 3-kinases (PI3K) found approximately 25% breast carcinomas. PIK3CA mutations cause overactivation PI3K/AKT/mTOR pathway lead resistance anti-HER2 targeted therapies breast cancers, involved response anti-mTOR agents proposed molecular diagnosis marker PI3K inhibitors. A highly sensitive method required detect PIK3CA mutations paraffin-embedded tumor tissues. Methods: We developed real-time PCR assay using allele-specific scorpion primers amplification refractory mutation system (PCR-ARMS) detect hotspot mutations exons 9 (E542K E545K) 20 (H1047L H1047R) PIK3CA PI3K. Results: PIK3CA mutations analyzed 102 paraffin embedded breast tumors (88 invasive ductal carcinomas 14 lobular ductal carcinomas). All specimens validated pathologist examination processed DNA extraction PCR. PIK3CA exon 9 20 mutations found 22.5% specimens, 39.1% exon 9 (26.1% E542K, 13.0% E545K) 60.9% exon 20 (17.4% H1047L 43.5% H1047R). These results comparable literature data (=0.327 ; p<0.05). PCR ARMS found highly sensitive, able detect 0.5 % mutated DNA. Conclusion: PCR ARMS assay highly sensitive PIK3CA exon 9 exon 20 hotspot mutations analysis breast carcinomas molecular marker anti-HER2 PI3K inhibitors response prediction. 18714 Background: The frequencies known driver mutation lung adenocarcinoma patients United States reported NCIs Lung Cancer Mutation Consortium (LCMC), indicating driver mutations detected 54% (280/516) tumors. In report, mutations found: EGFR 17%, KRAS 22%, HER2 0.6%, PIK3CA 1.2%, BRAF 2%, MET amplification 0.6%, MAP2K1 0.4%, NRAS 0.4%, AKT 0%, ALK rearrangements 7%. However little known ethnic difference driver mutation frequencies correlations driver mutations histological subtypes lung adenocarcinoma. Methods: Known driver mutations tumors 97 Japanese patients lung adenocarcinoma underwent surgical resection 1999 2003 National Cancer Center Hospital East analyzed next-generation sequencing confirmed Sanger sequencing. Correlations driver mutations histological subtypes also assessed. Results: Driver mutations detected 72% tumors. Mutations found: EGFR 57%, KRAS9%, HER2 2%, PIK3CA 2%, BRAF 1%, MET amplification 1%, MAP2K1 0%, NRAS 0%, AKT 0%. Due limitation rearrangement detection exon-sequencing, ALK rearrangements analyzed. Compared report LCMC, frequency EGFR mutations high KRAS mutations low present study. All mutations mutually exclusive. The number predominant histological subtypes tumors harbored EGFR mutations papillary 28, acinar 3, solid 5, lepidic 19. That KRAS mutations showed papillary 2, acinar 2, solid 2, lepidic 3, HER2 mutations showed papillary 1 acinar 1. Two tumors harbored PIK3CA mutations showed histological acinar pattern. Each BRAF mutation MET amplification showed lepidic papillary pattern, respectively. Conclusions: It suggested ethnic difference driver mutation frequencies lung adenocarcinoma Asian non-Asian patients, although details ethnic distribution included LCMC study opened. In addition, driver mutations correspond specific histological subtypes lung adenocarcinoma. 18715 Background: In patients metastatic colorectal cancer (mCRC), activating mutations within KRAS, result EGFR-independent intracellular signal transduction activation, found approximately 35-40% patients mCRC significantly associated lack response cetuximab panitumumab therapy. Although current guidelines recommend testing frequent KRAS codons 12/13 mutations, emerging data indicate additional KRAS BRAF mutations also predictive non-responsiveness anti-EGFR antibodies mCRC. This study aimed analyze prevalence low-penetrance KRAS BRAF V600 mutations caucasian mCRC population. Methods: A two-institution retrospective cohort 1,238 consecutive KRAS wild type mCRC patients previously studied 7 mutations codons 12/13 (G12D, G12A, G12V, G12S, G12R, G12C G13D) CE-IVD marked ARMS-scorpion real-time polymerase chain reaction PCR (Therascreen, Qiagen) assayed diagnostic TaqMelt PCR assay cobas KRAS mutation cobas BRAF V600 mutation tests (Roche), designed detect 19 mutations KRAS codons 12, 13 61 (including G12F, G13C, G13R, G13S, G13A, G13V, G13I, Q61H, Q61K, Q61R, Q61L, Q61E Q61P) BRAF V600 (V600E, V600K V600D) mutations. An additional cohort 146 KRAS mutated patients ARMS-scorpion PCR studied. DNA obtained cobas DNA preparation kit one single 5m formalin-fixed paraffin-embedded tissue section. Results: In samples, sufficient DNA obtained KRAS BRAF mutational studies. Among 1238 KRAS codons 12/13 wild-type patients ARMS-scorpion PCR,166 (13.4%) showed KRAS mutations, 117 (9.5%) codons 12/13, 49 (4%) codon 61. BRAF V600 mutations detected 9% cases. In ARMS-scorpion PCR KRAS mutated patients, mutations confirmed cobas cases. Conclusions: The cobas mutation tests robust reproducible assays that, 1) detects higher incidence (13.4%) mutations codons 12, 13, 61 KRAS gene wild-type mCRC population, 2) relevant rate BRAF mutations present population, 3) requires small amount tissue. 18716 Background: While majority lung adenocarcinomas (ADCL) harbor identifiable driver mutation, targeted therapies squamous cell lung carcinomas (SQCLC) lagged development due paucity druggable oncogenic events. Three targets, together occur 50% SQCLC, recently identified (FGFR1 amplification, DDR2 mutations, PIK3CA mutations/PTEN loss). Comprehensive molecular analysis SQCLC tumors The Cancer Genome Atlas ongoing, new therapeutic targets horizon. Methods: We instituted prospective, multiplex testing SQCLC tumors (Squamous Cell Lung Cancer Mutation Analysis Program, SQ-MAP). Tests include FISH FGFR1 amplification (defined FGFR1:CEP8 2 >10% cells), IHC loss PTEN expression, Sequenom MassARRAY PIK3CA mutations (and others, below). We also incorporating targeted exon sequencing (Agilent SureSelect/Ion Torrent) panel 80 lung cancer oncogenes tumor suppressors preparation future studies. All tests performed formalin-fixed paraffin-embedded samples Institutional Review Board/Biospecimen Utilization Committee approval. Results: 40 SQCLC patient specimens processed SQ-MAP 3 months. 8 samples excluded (insufficient tissue 4, reclassification ADCL 4). Data available 28 patients. PTEN IHC performed 15 samples date. Molecular results summarized table. Events non-overlapping. Results 80 gene sequencing component described. Based SQ-MAP, accrual 2 approved clinical trials (FGFR1 inhibition; PI3K inhibition) begun, third planned (DDR2 mutations). Conclusions: Actionable defects detected 60% (95% CI: 37-75%) SQCLC specimens. Mutation data 80 oncogenes tumor suppressors available shortly (including DDR2). SQ-MAP serves platform supporting personalized care research. Test Frequency 95% CI FGFR1 amplification 25% (7/28) 11-45% PTEN loss, complete 20% (3/15) 5-49% PIK3CA mutation 11% (3/28) 2-28% KRAS mutation 4% (1/28) 0-18% EGFR mutation 0% BRAF mutation 0% HER2 mutation 0% AKT1 mutation 0% NRAS mutation 0% MEK1 mutation 0% Any 60% 37%-75% Name: abstract, Length: 18717, dtype: object']\n"
     ]
    }
   ],
   "source": [
    "#combine abstract and title\n",
    "text=[text4,text3]\n",
    "print(text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 291,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "patient              0.640964\n",
      "mutat                0.639770\n",
      "cancer               0.602994\n",
      "lung                 0.475828\n",
      "egfr                 0.394871\n",
      "cell                 0.393319\n",
      "kra                  0.285974\n",
      "tumor                0.269258\n",
      "the                  0.231884\n",
      "alk                  0.208361\n",
      "braf                 0.199048\n",
      "diseas               0.195824\n",
      "pt                   0.194510\n",
      "studi                0.188898\n",
      "carcinoma            0.178391\n",
      "amplif               0.163704\n",
      "fgfr1                0.156778\n",
      "breast               0.155226\n",
      "adenocarcinoma       0.148301\n",
      "human                0.146271\n",
      "therapi              0.133256\n",
      "melanoma             0.132062\n",
      "non                  0.123942\n",
      "result               0.120599\n",
      "pik3ca               0.120241\n",
      "treatment            0.117375\n",
      "nsclc                0.117017\n",
      "tki                  0.110091\n",
      "inhibitor            0.108897\n",
      "respons              0.105558\n",
      "                       ...   \n",
      "dramat               0.002853\n",
      "drive                0.002853\n",
      "emphas               0.002853\n",
      "primit               0.002853\n",
      "privat               0.002853\n",
      "elimin               0.002853\n",
      "problem              0.002853\n",
      "electronmicroscop    0.002853\n",
      "electrocardiogram    0.002853\n",
      "product              0.002853\n",
      "eight                0.002853\n",
      "prognos              0.002853\n",
      "project              0.002853\n",
      "ecori                0.002853\n",
      "ecg                  0.002853\n",
      "prolong              0.002853\n",
      "promis               0.002853\n",
      "e746                 0.002853\n",
      "pronunc              0.002853\n",
      "e2f3                 0.002853\n",
      "proof                0.002853\n",
      "dy                   0.002853\n",
      "propos               0.002853\n",
      "propria              0.002853\n",
      "prostat              0.002853\n",
      "dual                 0.002853\n",
      "proteinuria          0.002853\n",
      "druggabl             0.002853\n",
      "prove                0.002853\n",
      "zytolight            0.002853\n",
      "Length: 2043, dtype: float64\n"
     ]
    }
   ],
   "source": [
    "#Cell to find top_words\n",
    "\n",
    "def tokenize(text):\n",
    "    tokens = word_tokenize(text)\n",
    "    stems = []\n",
    "    for item in tokens: stems.append(PorterStemmer().stem(item))\n",
    "    return stems\n",
    "\n",
    "\n",
    "# word tokenize and stem\n",
    "text = [\" \".join(tokenize(txt.lower())) for txt in text]\n",
    "vectorizer = TfidfVectorizer()\n",
    "matrix = vectorizer.fit_transform(text).todense()\n",
    "# transform the matrix to a pandas df\n",
    "matrix = pd.DataFrame(matrix, columns=vectorizer.get_feature_names())\n",
    "# sum over each title and abstract (axis=0)\n",
    "top_words = matrix.sum(axis=0).sort_values(ascending=False)\n",
    "print(top_words)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Creating not PM dataset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(13368, 4)"
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "notPmSet = data_with_features[data_with_features['pm_rel_desc'].str.contains('Not PM', regex=True)]\n",
    "notPmSet.shape"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
